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ABSTRACT
Given that research is based on innovation, it has been believed that its activities can only be optimized
with equipment upgrade, increment in personnel scientific knowledge, development of new analytical
software and/or changing the areas of study. After realizing the limited results achieved with these
approaches, lab representatives started to notice the opportunity of introducing process optimization tools,
such as Lean and Six Sigma, which showed success in manufacturing environments,.
This project analyzes the interrelation between process and results, providing a clear explanation of cause
and effect conditions, and a concise list of areas for improvement. Specifically, the document defines a
measurement system using process maps and key performance indicators (KPIs). With this, the document
describes the current state through historic trends, provides a complete data and root cause analysis for
current state description, and provides a process capability study for the available indicators.
Implementation of the steps mentioned above show how focus in lab turnaround times have been
deviating attention from more impactful improvements, which can greatly affect overall drug discovery
duration. Also, the analysis identifies that constant technology changes caused constant adaptation of
process procedures, which generated non-value added activities. These non-value added activities today
occupy about 50% of a lab associate's time. Lastly, historic data evaluation shows that root cause
statistical analysis is limited by the presence of a combination of special and common cause variations.
Some of the project recommendations include: incorporation of chemist's knowledge about compound
potency, integration of equipment and software information, change in booking system, incorporation of
assay and plate criteria, definition of standard procedures for specific activities, and integration of assay
development and data submission tools. Overall, these changes can lead to a 50% reduction in the
profiling times greater than 60 days, decrease of 62% and 60% in Compound Manager (CM) and
Compound Profiler (CP) non-value added times respectively, 30% decrease in CM and CP total duration
per assay plate, and increase in profiling time stability and predictability. Despite the fact that timing and
scale of available resources will impact the realized benefits, the proposed framework gives EPP the
opportunity to assess the improvements by their effect and alignment with goals.
Thesis Supervisor: J. Christopher Love
Title: Assistant Professor, Department of Chemical Engineering
Thesis supervisor: Roy Welsch
Title: Professor of Statistics and Management Science, MIT Sloan School of Management
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GLOSSARY
Food and Drug Administration (FDA): The FDA is an agency inside the United States Department of
Health and Human Services, which has the task of protecting and promoting public health. For this
reason, one of the main activities is to regulate and supervise products related to human health like
medical devices, pharmaceutical and biopharmaceutical drugs, and dietary supplements.
New molecular entity (NME): A NME, also called New Chemical Entity (NCE), is as a unique
compound that has not been previously approved by the FDA. NMEs are usually developed by companies
in early drug discovery stage, have been synthesized and will be employed and tested during Clinical
Trials.
Hit-to-Lead (H2L): Is the phase of drug discovery where many compounds are tested to find the best
combination of structure and activity for a particular target. At the end of the H2L phase, a compound
known as hit candidate is nominated to continue further tests.
Lead Optimization (LO): After the hit compound has been approved, the LO phase seeks to optimize
the chemistry of the compound such that activity, pharmacokinetics and pharmacodynamics are
maximized.
Lead compound: Compound selected at the end of LO phase, which optimally modulates the activity of
a receptor or other target protein. A successful lead compound becomes a drug candidate for further
development.
The National Institutes of Health (NIH): The NIH, as the FDA, is an agency of the United States
Department of Health and Human Services and is the primary agency of the United States government
responsible for biomedical and health-related research. Its mission is to promote global health by sharing
new knowledge in the biomedical arena.
Profiling assay and AC50 value: Also known as dose-respond curve, potency or inhibition assay, this
test seeks to measure the binding occurred between the compound and the target in evaluation.
Specifically, an assay is a procedure for detecting the presence, estimating the concentration, and
determining the biological activity of a compound-target combination 2. Assays are based on measurable
parameters that enable the evaluation of differences between samples and controls. This measurement is
given by the AC50 value, which represents the concentration of substance that provides 50% inhibition.
2 (http://www.dddmag.com/Glossary.aspx)
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Target: Is a DNA, RNA, or protein that is involved in a disease process and is a suitable for therapeutic
compound development. A target defines the type of disease research efforts and is the basis to develop
new compounds.
Compound: From a chemistry perspective, a compound is as a pure chemical substance consisting of two
or more different chemical elements that can be separated into simpler substances by chemical reactions.
In drug discovery, a compound is the chemical entity that is tested towards certain target and will be
optimized further if its activity looks promising.
High Throughput Screening (HTS): Automated profiling process that uses a large number of assays to
identify active compounds. HTS analyzes large numbers of compounds, resulting in a less costly and
faster process.
Positive Control and Negative Control: These are wells in an assay plate that are used as boundary
control. They set the range for expected IC50 values. Positive control confirms that the experiment
conditions have a positive result, even if none of the compounds result active. Positive controls are assay
wells that contain only enzyme, so, these wells show maximum enzyme activity. In the other hand,
negative control defines the lowest possible, given that these wells contain no enzyme.
Reference compound: Is a compound with known activity for a specific target. These compounds are
used in enzymatic assays as quality control. They allow analysis of trends and differences, not only across
assays but also in different repetitions of the same assay.
- 12 -
1. INTRODUCTION
1.1 Project Drivers: Current Challenges in Drug Discovery
The pharmaceutical industry is facing a difficult period with increasing R&D expenditures, Food and
Drug Administration (FDA) changing towards more complex new drug acceptance criteria and fierce
competition among all the players. Increase in regulator's requirements, combined with the challenges to
discover new targets and/or novel medical entities (NMEs), forces drug manufacturers to focus on time-
to-market and cost allocation. While time-to-market allows companies to start investment recovery early
on, adequate cost allocation ensures financial stability after products loose their patents. When evaluating
the complete pharmaceutical process, drug discovery stands out with the most duration and need for
resources. Because of this, optimization of Research and Development (R&D) can impact overall
company results3 .
In response to the current pharmaceutical industry status, Novartis has shifted research strategy to focus
on discovery projects that address the patients with greatest medical needs while enabling the
development of a powerful scientific knowledge. Consequently, Novartis Institute for BioMedical
Research (NIBR) integrated Scientific Centers for particular Disease Areas and formed Expertise
Platforms committed to technologies and procedures of specific scientific fields. At the Expertise
Platform Proteases (EPP), where this project is developed, Biology (BIO), Medicinal Chemistry (MCH)
and Structural Sciences (STS) teams focus on discovery and optimization of novel compounds to deliver
highly selective drugs which inhibit proteases, one of the main target classes in the human genome. These
teams also work in collaboration with all Disease Areas for projects developed in and out the platform.
Beside organizational changes, Novartis has been implementing new ideas in both, manufacturing and
R&D. For manufacturing, Novartis followed the initiative of other companies in adopting process
improvement tools to achieve cost reduction and quality enhancement while stabilizing the company's
profits. In the case of research, Novartis has been incorporating innovative technologies and diverse
automation, such as High Throughput Screening (HTS) and combinatorial chemistry. Despite of
observing some benefits, soon after the first technological upgrades were in place, R&D costs started far
outweighing the observed gains. At this point, it became evident that sustainable benefits could only be
- 13 -
3 (Steven Paul, 2010)
achieved by a change in the status-quo, creating an expectation of the possible outcomes if process
optimization tools were to be applied4.
1.2 Problem Statement
The journey to adopt and implement process optimization tools in research has been a challenge for drug
manufacturers. Difficulty rises when focusing on upgrading time consuming and costly discovery
processes with extremely high failure rates. Risks in drug research rely on the unpredictability of the
compound's behavior towards certain target and are limited by the scientific knowledge. In addition to
this "natural" variability, lack of reproducibility and repeatability of results adds to the variability of
defining a therapeutic candidate, further increasing research uncertainty. As a result, many improvements
can be obtained by the implementation of standards and the use of common methods among laboratories,
which can decrease process variability but also facilitate improvement of equivalent tasks and decision-
making processes. Lastly, standardization can also facilitate comparability of results across research labs.
EPP has been transforming operations within the Biology Unit (EPP/BIO), obtaining significant reduction
of assay turnaround time. Despite these efforts, hurdles on critical project resolutions, a demanding work
environment, and constant change in laboratory methods have created limited communication among
players, causing internal discomfort with EPP's overall results.
Consequently, this project comes as a first approach for specific process analysis to deeply evaluate EPP's
procedures within Hit-to-Lead (H2L) and Lead Optimization (LO) Phases of Drug Discovery, define
impactful areas of improvement based on process analysis, identify key stakeholders, and evaluate the
alignment of expectations and capabilities.
1.3 Thesis Overview
The document has the following structure:
Chapter 1 describes the drivers of the project and the general outline of the document.
Chapter 2 illustrates the pharmaceutical industry's dynamics and limitations, along with the specifics of
NIBR and its role in Novartis drug discovery process.
Chapter 3 states the hypothesis and the project approach.
- 14 -
4 (Pollok, 2005)
Chapter 4 shows the details of EPP's process analysis and explains the method for defining the proposed
measurement system.
Chapter 5 presents a thorough analysis of the data for each one of the indicators of the proposed
measurement system. The analysis is explained individually for each indicator defining first the current
state using historic data evaluation, then listing and evaluating possible root causes, and finally realizing a
study of the process capability.
Chapter 6 provides a summary of the results, lists specific recommendations and their impact on EPP's
performance, presents internal challenges that can limit the implementation of the proposed solutions, and
suggests future areas of study.
- 15 -
2. BACKGROUND
2.1. The Pharmaceutical Industry
In a general, a company in the pharmaceutical industry discovers, develops, manufactures, and markets a
variety of medicinal goods, from life saving to health improvement products. Given its nature, the
pharmaceutical industry is subject to a large variety of laws and regulations regarding the patenting,
testing and marketing of drugs. These laws and regulations depend not only on the type of drug but also
on the specifics of application, patient focus and location (selling and manufacturing)I'6.
The complete process from discovery to manufacturing of a pharmaceutical product can take anywhere
from 8 to 12 years, with an overall average cost of $800 to $1,200 million7. The specific duration and
costs depend on an infinite number of variables such as the target, complexity of the pathways, properties
of the compounds in evaluation, number of patients, and even location of clinical trials. A diagram with
the phases and an average duration is shown in Figure 2. In the new drug application (NDA) step, the
drug is approved and further phases include manufacturing, marketing and distribution.
TV" *ID Sasofqt es r"~a D4MOVA~pu
Avg=? Averap-4 yams
Ia _M **IF*
Figure 2. Classification of pharmaceutical industry phases, from discovery to market8
From all the value chain of drug manufacturing, the most costly and risky portion is discovery, including
clinical trials. Table 1 presents some numbers for costs and probabilities of success for each phase of drug
discovery. In a more comprehensive manner, Figure 3 compares the average risk (related to the
probability of success) and the value creation over the total time from discovery to market (assuming total
duration of 20 years).
5 (United States Department of Labor, last modified: December 17, 2009)
6 (World Health Organization (WHO), 2004)
7 (Fee March 01, 2007)
8 (Adapted from Fee, March 01, 2007)
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Table 1. Average industry costs and probabilities of success for drug compounds9
Cost (M) Probability (%)
Phase I $2-10 70
Phase II $5-50 25-35
Phase III $30-$100s 25-35
Aggregate $50-800 4-10
Median $250 8
1000. 1000
900% ___ 900
80% 800
701% 700
e 60% -600
. 0%1 500 >
4 0%0' 400
30% 300 ;>
20% 200O
10% 100
0% 0
0 2 4 6 8 10 12 14 16 18 20
Time, t (years)
Figure 3. Cost and risk average values for pharmaceutical companies for 200910
In Figure 2, clinical trials end after about 10 years, causing the steep decrease in risk and increase in costs
at that time. After that step, additional costs represent manufacturing, marketing and other costs related to
making the drug available in the market. Uncertainties after this stage only depend on selling and
manufacturing constraints, but are negligible when compared to a compound starting tests or a non-
patented drug. Given the combination of risk and costs, value creation peaks up when drugs have
sufficient studies to demonstrate effectiveness to regulators.
Along the years, pharmaceutical companies have been trying to discover novel compounds for unique and
un-studied target pathways. Given mentioned costs and uncertainty, along with an increase in
prerequisites to receiving a patent, investments in research have been increasing with disproportional
results in new drug discovery. Most of the current critiques regarding the increase R&D expenditures are
based on the decrease in the number of registered NMEs. Figure 4 shows a graph with the trends of R&D
expenditures, approval of NMEs, and other metrics that characterize the trends of pharmaceutical industry
from 1980 to 2010. As Figure 4 shows, in the 1980's and 1990's, companies spent close to 17% of their
9 (Fee March 01, 2007)
10 (Modified from United States Department of Labor, last modified: December 17, 2009)
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revenues in R&D. These days, that number has gone up to almost 20% while the number of NDA
presents a steady (if not a decrease) trend". Even when some experts argue that current focus has been on
improving current approved therapeutics and/or increasing the number of disease treated by established
indications, is still unclear how sustainable is spending trend in pharma R&D.
12Figure 4. Diagram of average pharmaceutical industry dynamics over the last 30 years
2.2. Novartis AG
Novartis is a multinational pharmaceutical company with headquarters located in Basel, Switzerland. It
was created in 1996 through the merger of Ciba-Geigy and Sandoz. In 2009, Novartis was ranked
number one in revenues and number three in sales ($44, 267 millions in 2009)13. Novartis has been
growing not only in the pharmaceutical markets but also in the areas of vaccines, generics and consumer
health, reaching almost 100,000 full-time employees around the world.
Novartis Pharmaceuticals has a portfolio including several disease areas such as Cardiovascular and
Metabolism, Oncology, Neuroscience and Ophthalmics, Respiratory, and Immunology and Infectious
1 (Food and Drug Administration Last updated: August 12, 2009)
12 (Taken from www.veomed.com, Medical Student Visual Learning Resource)
13 (Novartis Company Website)
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Diseases. In this collection of areas, Novartis has more than 50 marketed products, many of which are
14leaders in their respective therapeutic areas
To maintain the mission of discovering and developing innovative products, during 2008 Novartis
increased R&D investments by 12 percent to USD 7.2 billion. This is one of the highest numbers in the
industry relative to sales (17.4 percent) 5 . Figure 5 shows the increment of Novartis R&D expenditures
over time, from 2004 to 2008.
2008 7.2(17)
2007 6.2(17)
2006 S (1S)
2005 4.8(16)
2004 4 (16)
0 2 4 6 8
Figure 5. Trend of investment with respect to sales for Novartis' 6
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical unit within
Novartis, with about 5,000 associates distributed in 4 countries (US, Switzerland, UK and China). In
order to boost discovery, NIBR has focused on developing key competencies in distinct areas, by
combining automation, robotics, computational science, biology and chemistry into diverse expertise
units. The objective with this approach is to have a strong scientific knowledge in a specific arena that
collaborates with any discovery project across research.
Three main divisions were developed during the implementation of mentioned approach for
improvement: Discovery Science, Clinical Sciences and Disease Areas. Clinical Sciences bridge bench
science and clinical medicine by optimizing the performance of a new drug through drug metabolism and
17pharmacokinetics, and by employing translational medicine to interpret biology into medicine
The Disease Areas group applies its knowledge to specific categories of therapeutic field. Some of the
areas involved are Autoimmunity, Transplantation and Inflammatory Disease (ATI), Cardiovascular and
Metabolic Diseases, Gastrointestinal Disease, Infectious Diseases, Oncology , Ophthalmology, and
Respiratory Diseases.
14 (Novartis Company Website)
(Novartis Company Website)
16 (From Novartis Company Website)
17 (Novartis Company Website)
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Lastly, Discovery Sciences focus mainly on developing technological expertise to create a common
approach towards similar disease mechanisms. Some of the areas covered by Discovery Sciences are
biologics, biomarker development, imaging, metabolisms, pharmacokinetics, preclinical safety, and
proteomic chemistry. This last unit, known as the Center for Proteomic Chemistry (CPC), brings together
biology and chemistry to study the interactions of small chemical molecules with biological
macromolecules, generally proteins. The CPC group studies compound-target interactions by biophysical,
protein structure, and cheminformatics approaches. Validated hits with the desired properties are passed
18to Global Discovery Chemistry (GDC) for further optimization
To create more specialization and support to each disease area, CPC has established three platforms; two
dedicated to target families, Expertise Platform Kinases (EPK) and Expertise Platform Proteases (EPP),
and a group dedicated to natural products research. With this structure, CPC's capabilities include high-
throughput screening, preclinical safety profiling, characterization of protein structure, discovery of
19natural products discovery, and research of protease and kinase targets' .
EPP plays a vital role in NIBR given its focus on one of the main targets in the human genome. In
general, EPP is involved in the discovery and optimization of compounds to deliver highly selective drugs
that inhibit proteases. As shown in Figure 6, all areas are involved in each of the projects developed
compounds in a shorter time. Complementing Figure 6 within the unit, creating a teamwork environment
Figure 9 presents the involvement of each group throughout research and describes teamwork among
units.
- 20 -
18 (Novartis Company Website)
19 (Novartis Company Website)
Novartis - Expertise Platform Proteases (EPP)
An Integrated Approach
Amysmp drwneird Targtvon
cry ownum. a Clinical
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Focusad Nrates
Fi e 6E he ntegrate workbetwna
Figure 6. EPP diagram showing the integrated work between units20
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Figure 7. Phases of Novartis R&D and involvement of groups within EPP"l
2.3. Recent initiative for drug discovery optimization
Starting about a decade ago, companies in all types of industries began implementing process
optimization tools to control and systematically decrease costs while achieving better quality in the fmnal
product, service, or any metric used to evaluate customer satisfaction. In general, any tool used for
21 (Modified from EPP's internal documentation)
(Modified from EPP's interal documentation)
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process improvement aims to find activities that deviate resources from creating value towards the final
needed result.
Margins that characterize the pharmaceutical business have sometimes been observed as a limitation to
encourage process optimization. As discussed in previous sections, when companies started to observe the
decrease in new drug discovery despite high investments, along with an increase in customer awareness,
and the shift of the FDA towards quality design into drug products, the need to focus on the way
processes take place became evident. At this moment, tools like Lean and Six Sigma started to be
implemented in pharma operations.
Novartis Pharmaceuticals started their internal approach towards process optimization by introducing
IQP, which stands for innovation, quality and productivity. IQP is Novartis initiative to implement Lean,
Six Sigma and other methodologies in their manufacturing facilities around the world. This approach "is
different to the [s,c] traditional management styles focusing on short term 'quickfix' solutions rather than
22,,
on identifying the problem correctly and ensuring the solution is effective and sustainable long-term
Today, Novartis goal is to use these methods on drug development.
But even when advantages are obvious, the innovative and unpredictable nature of research has been
stopping drug discovery from adopting these tools. Most of the scientists that work in research believe
that standardization is the death of creativity and that, if restricted procedures are in place, novelty of
discovery will be gone with it.
To overcome these fears, experts in process improvement have studied and piloted these tools in research
laboratories. Interestingly, pilots revealed a strong correlation between innovation and standardization. An
explanation to this relation is that results start with innovation, but their reproducibility comes from
standardizing that innovation. In this way, innovation is required to identify targets and compounds, to
understand scientific pathways, and to develop assays, but standardization is necessary to ensure
consistency in the tests, to specify further assays, and to warranty reproducibility of inhibition down the
road. Also, standardization forms the basis for further, process improvement, and innovation enables such
improvement. In this way, process optimization can form part of the dynamic research loop 2 3.
Accordingly, application of process improvement tools in pharmaceutical R&D focuses on identification
of common processes, which can be further optimized by reducing waste in the system, finding benefits
of process control, and observing opportunities for standardization. One of the most impactful results of
22 (Next Generation Pharmaceutical, 2010)
23 (Goodman, 2010)
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process improvement in drug discovery is the reduction of variation in potency results, leading to an
increase in predictability and reproducibility of compound's data. Because Lean-Six Sigma provides a
structured and data driven path for improvements, this tool has high potential in the highly scientific
environment of R&D, generating also an increase on workers' engagement 24.
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3. HYPOTHESIS AND PROJECT OVERVIEW
3.1. Hypothesis
Critical differences between common manufacturing processes and laboratory procedures have created
the paradigm that research cannot be optimized, at least without giving away some of the key benefits that
process improvement brings or limiting science. Even when bringing drugs to market is surrounded by
unpredictability, limitations faced by drug discovery R&D are not unique and can be compared with other
industries where process optimization has been achieved. Understanding the needs of all the players in the
H2L and LO loop, how these needs fit into EPP's overall strategy, and where improvements need to
occur, is key for ensuring concrete long-lasting benefits through process analysis.
In order to create a framework to evaluate EPP's operations, this study divides the study in three
categories: quality, effectiveness and efficiency. These categories allow a thorough evaluation of the
current processes and facilitate evaluation of improvement areas.
The current need for streamlining processes within EPP comes from years of profiling upgrade attempts,
focus on narrow indicators for measurement of performance, lack of process analysis, and need for
implementing methodological procedures. Known tools such as Lean, Six Sigma or Novartis' IQP could
offer a great impact in EPP's organizational performance, without requiring major investments or drastic
modifications to actual procedures.
3.2. Project Scope and Approach
Even when H2L and LO specifics differ for every disease target and scientific study arena, general
methodologies are comparable. Based on the above-mentioned limitations for process improvement, the
aim of this project is to closely look at EPP's procedures, understand its dynamics, and create a
foundation for the improvements application in other labs within research. As a result, this project
applies an integrated approach, incorporating decision-making methods in daily activities, while creating
a measurement system that reflects and aligns overall research mission. With this, internal performance
can be tracked, operations within different labs can be compared, and best practices can be shared, thus
resulting in a detailed breakdown of strengths and weaknesses, to frame final recommendations. Figure 8
shows the main area of study derived from the hypothesis and outlines general study objectives.
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Figure 8. Diagram of the three main areas covered by the project
The project approach can be divided into two main routes: Process Analysis and Data Analysis. The first
seeks to defme a detailed description of the current activities while the second provides an understanding
of historical results and observed process behavior. With the interconnection between procedures and
resulting data, root causes can be revealed and important areas for improvement can be established.
Figure 9 broadly describes the mentioned routes and the tools to be utilized in each case.
1.PROCESS
ANALYSIS
2.DATA
ANALYSIS
HOW? HOW?
SIPOC Current state: Patterns In data
VOC Potential root causes
Process Map Statistical analysis
Capability analysis
Verify and quantify root causes
RECOMMENDATIONS
Figure 9. Diagram of project approach showing the two main stream focuses
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e In-process quality controls
*Factors that affect test's
quality
-Standard process evaluation
-Decision-making procedures
* Process flow analysis
eLab capabilities
-Communication between
stakeholders
4. PROCESS ANALYSIS
Although Novartis is strategically separated in functional units, i.e. research, development, marketing, and
finance, significant activities and decision-making processes occur in their interface. Collaborations,
cross-unit teamwork, and knowledge-based assessments underline a continuous flow of information
across departmental borders.
Given that information is the most important outcome in every activity within drug discovery, the aim of
this chapter is to apply a process-based view to EPP's activities; understand the processes, fully examine
the transfer of information, and define the role of process flow, organizational structure and information
systems towards efficient research metrics2 . If compared to Novartis' IQP program, this chapter covers
the Scope and Seek phases.
4.1. Process Mapping
The first step towards identifying opportunities is to completely understand the process steps and their
dynamics. Process mapping is a visual representation of workflow activities, and is applied to generate a
real view of how steps take place and stakeholders interact.
Although different types of maps and diagrams have been developed and used while optimizing
processes, it has been concluded that the outcome is independent of the method used, if real process
knowledge and critical judgment are developed. In other words, the real impact is achieved when the
process analysis creates a deep understanding of current gaps and shows clear opportunities for
improvement. For this reason, process mapping for EPP is developed in three steps, gradually adding
more information to create an accurate picture of the current flow. With an accurate current picture,
research dynamics are compared to the optimal state and gaps are further assessed.
The first representation is shown in Figure 10, corresponding to the H2L and LO loop diagram when the
Chemistry Lab produces new compounds. The diagram resembles what is known as High-Level Process
Map or Relationship Map, which, by definition, shows the interface between internal and external process
stakeholders26
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CHEMISTRY LAB
at EPP/MCH
Powder and/ CMPD
4, ... or TRT request
CMPD PROFILER IC50 data Solution
at EPP/BIO
CMP ... Assay ready . MPDplates
CMPD MANAGER
at EPP/BI
2,
CMPD HUB
at LFP/NCA
Figure 10. General description of H2L and LO loop in EPP and outcomes of each step
Let's assume that chemistry has synthesized a new chemical compound intended to develop a novel
therapeutic. As shown, the loop starts when MCH produce the new compound that needs to be tested
against a particular disease target. The compound, most of the times produced as a powder, is delivered to
the NCA and required experiments are entered in the ordering system called Test Request Tool (TRT).
Once in the NCA, a copy of the compound is produced and a vial with a standard dilution is delivered to
each laboratory specified in the chemist's request. As of December 2009, the NCA was delivering one
vial for each test requested by the chemists, even if the tests were performed in the same laboratory.
Each vial that arrives to the EPP/Biology laboratory is picked up by the Compound Manager (CM), who
sorts the compounds and prepares the plates with compound's dose-response curves (DRCs). The
outcome of this process is a plate containing a serial dilution of the compounds to be tested, including the
reference compounds that correspond to each experiment.
When ready, the plates are distributed to the Compound Profilers (CPs), responsible for determining
compound inhibition (expressed as IC50 value) towards the target(s) requested by the chemist. After
experimental data is generated, results (IC50 values) are provided to the chemists.
As the final step, chemists analyze compound data by relating it with the compound's structure and
comparing obtained behavior with related compounds. This compound relation is critical for knowledge
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building and will define the next compound to be tested. After this step, new chemical structures are
defined and the loop starts over again. Iteration will continue with the framework showed in Figure 10,
until a candidate that satisfies decisive pre-defined criteria is discovered.
The next tool for process analysis is the Cross-Functional Map (comparable to a Deployment Flowchart).
This map shows the process flow and identifies who is in charge of each activity and when they take
place2 7 . Cross-Functional Map for EPP's discovery process is shown in Figure 11.
Figure 11. High Level Cross-functional Process Map for H2L and LO phases in EPP
The interest in applying this tool is to facilitate discovering who is performing which task, when, where
and how long. From the figure above, it is observed:
1. Chemistry starts and closes one loop, defines the number of iterations and relies completely on
EPP/Biology's output to define the next steps.
2. CM's activities are constrained by CP's scheduling and are the ones with the key process of tracking
compound position in each well of the assay plate. This compound position is linked to final results and
the correctness of upcoming steps relies on the correct track of this position.
3. CPs has the responsibility of performing the assay for each compound under the conditions stated by
the protocol, and submitting the final data to the chemists. Systematic and detailed analysis of the potency
obtained is critical to ensure data reliability. This data will impact directly the decision-making process of
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the medicinal chemists.
Now, building on the process knowledge acquired until this point, the SIPOC map is also completed and
shown in Figure 12. SIPOC stands for Suppliers-Inputs-Process-Outcome and Customers and not only
describes general activities as in the Cross-Functional map presented in Figure 6, but also shows what are
the inputs needed for the process, what do each step generates, and how every output affects and
determines the performance of the following activity.
Figure 12. SIPOC Map for Hit-to-Lead and Lead optimization phases of drug discovery in EPP
The main reason for utilizing SIPOC maps is that they help understanding the relationship and
dependence between the EPP platform and other groups involved in the discovery loop under evaluation.
Consequently, the SIPOC map provides a framework to observe specific activities in EPP and relate them
to the up and downstream procedures. In this way, the SIPOC map sketches what are the up and
downstream needs for every stakeholder and help to recognize what will be the impact in downstream
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stakeholder's procedures if any internal process in changed. In the same way, it also allows to look at the
changes that have to occur in the upstream processes to achieve improvement on internal procedures.
From this plot, it is observed again the disruption CP's scheduling has in CM's process flow: CMs will
generate plate copies only if the compounds were previously requested by the CP responsible of the
assay. As presented, CMs will consider scheduled CP's assays after realizing all the preparation of the
assay plates. If the profiling is not scheduled, prepared assay plates will be stored until the request is
generated.
At this point, information regarding stakeholder's interaction through the discovery loop and general
procedures in the lab has been obtained. Now, attention is shifted towards expansion of the EPP/Biology
lab's activities to fully understand the current state and its dynamics. For this, a Detailed Process Map is
developed.
By definition, this type of map allows process evaluation and potential root cause identification 28. Figure
13 and Figure 14 show the Medium Detailed Maps for CM and CP's summarized activities. Appendix A
through D show all steps inherent of each summarized activity and Appendix E shows the shape's key
used in the maps.
Particular observations from the diagrams are:
- Technology has been upgraded and processes changed mainly as a way to further decrease compound
profiling times. Limitations arise when continuity of changes blend with lack of analysis of their impact
giving a wrong perception of real obtained benefits. In addition, time for the learning curve to stabilize
has not been provided, resulting in the observed pile of steps that limit fluent workflow and divert
personnel from standard methods.
- Despite of having great information technology databases for the company as a whole, the EPP Unit has
mostly developed their own communication systems. Because of convenience and straight-forward use,
Excel has been widely used as the tool for data storage and transfer of information between individuals in
the lab. Satisfactory short-term benefits were observed until the amount of data started to reveal Excel's
limited capabilities when used as a database. Additionally, since Excel files and macros are developed
internally, responsibility for support, modification, and replacement relies on the same lab resources,
creating also delays in needed upgrades.
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- From process flow observation it is clear how the number of requests received in a particular day, the
total number of compounds tested, and the CP's scheduling procedure are approached as independent
steps. Therefore, even when the lab capacity allows for a smooth process flow, lack of coordination
creates oscillation of turnaround time and unsteady workload among lab associates.
PROCESS MAP -EPP:BO;COMPOUND MANAGER
3. RACK PMI
$CAN 4!5tbCA
PREP FOR
'TUBE
7. SORTING
T. soR TWO
PROBLEM
SOLVING
Figure 13. Medium Detail Process Map for Compound Manager
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Back to step ia
Back to step ia.
Figure 14. Medium Detail Process Map for Compound Profiler
- Focus on achieving low turnaround times seems to be the main limitation for process upgrade. Lack of
a complete set of performance indicators that align stakeholder's incentives towards a common objective,
is created by the individualized focus of daily work. Divided efforts decrease teamwork, not only among
internal laboratory groups but mostly between key players along the H2L and LO iteration. This generates
the observed unnecessary file storage (just in case backup), addition of non-value added activities to
speed up the process, and non-standard procedures. Unclear bottlenecks and milestones are the bottom-
line result.
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After analyzing the current flow at the EPP/Biology labs, it is evident that root-cause and value-added
activities need to be addressed. Knowing the lack of performance indicators and observing its effect on
profiling methodologies, the next phase concentrates on defining a common framework for project
evaluation that connects all different incentives into a common measurement system.
4.2. Voice of the Customer and KPI identification
It has been a topic of great discussion among crucial stakeholders whether the term customer is applicable
to the drug discovery, and if the use of this expression will have an adverse impact on achieved
teamwork. Even when collaboration is reinforced through all projects in EPP, at the end of the day
chemists have the task to pull all the data together and will be the main judges when deciding future
compounds for analysis. Also, chemistry is the final stakeholder in the analyzed drug discovery loop.
Therefore, in this study, chemistry is considered the final customer of the EPP/Biology laboratory and all
the tools that Lean, Six Sigma, and IQP provide for customer satisfaction are applied to the chemists.
The first tool to be utilized is Voice of the Customer (VOC). VOC is a set of tools that permits specific
understanding of what the customer wants and translates it into measurable indicators, often called
Critical-to-Quality (CTQ) variables2 9 . In general, VOC is used to understand the customer's (chemist)
needs when performing their internal processes, and define the gaps between the current and the ideal
delivery. In addition, VOC is utilized to evaluate the lab's flexibility to adapt to the changing environment
in the chemistry unit 30. Lastly, to ensure sustainability in the future, when VOC is applied in this project,
indicators are evaluated against EPP Unit's strategy requirements. In this way, when selected, KPIs are
not a collection of ideal chemist's outcomes, but a list of measurable and impactful indicators that will
help EPP achieve the platform's strategic mission.
VOC determination for EPP is based on several interviews with specific groups, including project team
heads, key chemistry laboratory heads, and lab associates. This method is commonly referred to as
proactive data collection.
During the discussions, three main observations always came to the table:
1. Why in some circumstances if one particular compound is tested at different periods of time the IC50
result can vary significantly?
29 (IQP Novartis website)
30 (Army Business Transformation Knowledge Center, 2009)
31 (IQP Novartis website)
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2. Why when several compounds are requested for the same profiling assay on occasion results are
submitted with considerably different times?
3. Why when one profiling assay is requested for several compounds on occasion results are submitted
with considerably different times?
Complete evaluation of chemist's concerns and their classification based on the approach are shown in
Table 2. As observed from the summary, all the issues listed in every category (quality, effectiveness, and
efficiency) have an impact on basically the same results, like profiling yield, turnaround time, and data
quality. This aspect shows hoe meaningful results can be achieved if improvements are focused on these
specific areas. Also, this frames the basis for the measurement system.
The next step compares all the issues expressed by the chemists with every activity graphed in the process
maps. This procedure helps finding the causes that are impacting, directly or indirectly, the results
perceived by the chemists. These causes, known as Customer Key Issues, reflect critical specifications
that characterize the alignment between EPP's laboratory deliverables and chemist's decision-making
process. This step helps decide where improvement efforts should be focused, what the key drivers for
customer satisfaction are, and what the baseline for a holistic measurement system is32
The first concern listed is the difference in inhibition values. The principal observation here is the lack of
a specific threshold that defines an acceptance range for a compound value. Because of unpredictability of
compound's potency and uncertainty in discovery, many argue that a rigid threshold cannot be stated.
With the aim of explaining the importance of setting an acceptance range for compound's potency, here is
a possible scenario: Let's assume that one of the teams is focused on Project A, and that compounds are
separated in groups based on their scaffolds. Now, assume that today compounds from every group are
requested for profiling. One of these compounds is compound C, from group 1. After d days, results are
submitted and the compound's C potency value is X.
After several compound iterations and structure analysis, the project team selects the scaffold from group
2 to continue in further discovery phases. Following numerous tests, finally the project reaches D3 phase
(lead optimization), when selectivity and efficacy of compounds in animals starts to have the most
significance. Results in this phase turned out not to be as promising as expected, and the project team had
to go back to the first generated data to select a second series compound. Let's assume that the second
best group is group 1, and already tested compound C is now selected to be the one in further research.
Compound C is requested by the chemists for confirmatory tests and the result is an AC50 15 times
(Army Business Transformation Knowledge Center, 2009)
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higher than. At this point, debate about assay accuracy and test repetition begins.
Table 2. Relation of VOC issues with observations from the Process Maps
ISSUE IMPACT RESULT
QUALITY
1. Chemists have - Difficulty for Bio Lab to set KPI -Repetition by MCH
different definition -Change in project team set different - Dissimilar threshold's selection for active
expectations from lab cmpds33 and unequal criteria in the lab
2. Unequal criteria -Heterogeneous data quality -Subjective curve fitting
used in the lab -Misalignment of required principles -Repetition by MCH/profiler
-Change in project team/profiler gives data
variation
3. No report of minor -Decrease in assay data reliability -Repetition by MCH
profiling - Cmpd selection can be done in different/ -Incorrect thresholds for active cmpds
modifications incomparable conditions
EFFECTIVENESS
1. Upgrading in -Investments for improving possible -Overcomplicating simple processes
technology not in constraints that can be addressed by process - Excel sheets and macros become a "need"
process analysis variations for profiling
- Processes are modified to match machine - Overcapacity in the lab
procedures -decreases process - Unclear installed capacity and capabilities
standardization
- Lack of real bottleneck determination
2. Process -Missing opportunity for best practices -Difficult interactions among the lab
modification is - Process owned by individuals -- reduces -Nonstandard procedures
performed team work and - Non-optimized processes
individually - Limited empowerment for improvement - Uncertainty in lab capacity/capabilities
EFFICIENCY
1. Expected IC50 - Assay repetition for active cmpds -Increase in data delivery time
range not shared -Imprecise lab turnaround time
-Decreases plate optimization - min # of
cmpds used in the repeated plate
-Assay time variable/unpredictable
2. No centralized -Excel sheets with macros developed to -Data backup in excel files - nonstandard
info/limited communicate and get data procedure traceability difficulties
automation - Copy/paste and manual record is needed -Overcomplicating internal processes/need
- Time in the lab is focused on process of "macro expertise"
management - Influence in lab interactions
-Turnaround time variability/predictability
3. Non-standard -Difficulty to keep track of lab -Turnaround time variability/predictability
processes activities/process improvement -Increase process complexity - cmpd
- Any variation in responsibilities impact manager, data for chemist
process and discrepancy on expectations
In order to define which data point is the accurate one, compound C is tested a third time, so that, if the
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third test shows an IC50 of l0X, the team will go with the fact that the compound has an inhibition in the
10X tol5X range. But, if the third assay result shows an IC50 of 5X, the project team will define the real
value of compound C to be in the X to 5X range.
The example's value is to reveal the importance of potency data correctness: an incorrect data point will
lead not only to wrong decisions, but also to an increase in the non-value added compound discovery
time, and, as a result, in an increment of research costs. Therefore, it is recommended that a set of tools is
defined to evaluate data quality and reveal accuracy of profiling processes. One useful method is the
definition of an assay's repeatability range through statistical analysis of the reference compound's data.
Another observation when applying the VOC tool refers to turnaround time variability and its impact in
chemistry processes speed. If a chemist wants to test two compounds that belong to the same project,
most of the time they will pause project activities until both results are received. The same situation
occurs when chemists need the same compound to be tested in several assays for selectivity analysis.
Most of the time, no substantial progress occurs until all data is gathered together. Because chemists
support their decisions in laboratory results, variability in the time lab results are submitted causes
variability in the time chemists provide the next series of compounds, amplifying further variability in the
overall project length.
Bringing all back to the VOC tool, it can be said that discovery time length is described mainly by two
variables: length of one iteration and number of iterations. If phases after D3 remain unchanged, time-to-
market can be decreased with improvements in discovery, when the number of iteration loops and/or the
time it takes for a single loop to be completed are reduced. Length of iteration is defined by the speed
each of the individual tasks can provide, while the number of iterations is affected by the assay
reproducibility and repeatability. These are the results of the VOC and the baseline for KPI determination.
Figure 15 shows a diagram of the discussed results.
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Key Performance Indicators (KPIs)
Figure 15. Voice of the customer (VOC)
4.3. Measurement System determination
Key Performance Indicators (KPIs) are specifications or measurements critical for business success,
characterized for being quantifiable, measurable and result-oriented. At a corporate level, KPIs align any
process with overall company goals, while at a unit level they reflect the objectives that describe the
activities of a particular unit3 4. The main advantages of having performance indicators is that they allow
process owners to monitor day-to-day tasks, promptly observe unexpected results, and take immediate
31
actions towards process constraints, having an instant and continuous influence on personnel actions
The aim of this section is to define a set of variables that allows laboratory associates to focus on simple
day-to-day goals while having a direct impact in overall platform performance. Tying realized VOC
analysis back to Novartis corporate strategy -deliver novel therapeutics in the shortest time possible- KPIs
for EPP should combine profiling speed with data reliability in order to create a comprehensive
measurement system.
The EPP Biology lab is currently using a modification of a program that was developed for High
Throughput Screening (HTS). Because of the number of compounds profiled and the nature of the
process, HTS deals with large number of datasets and provides many variables to expedite observation of
potent compounds. A total of 100 available indicators are displayed for the associate. Because EPP has a
more dedicated approach, more than 50 out of the 100 available indicators are not presently defined in the
3 (IBM)
3 (Drug discovery: are productivity metrics inhibiting motivation and creativity?, November, 2008)
- 37 -
system or calculated for the user. This large selection of variables has promoted the use of different
quality standards for evaluating assay results, creating an actual obstacle for standard quality procedures.
Thus, measurement system definition looks at the set of variables presented by the software and analyses
them from a data quality and robustness perspective, not depending on the current usage and/or
acceptance among the personnel.
While evaluating the list of metrics displayed by the software, attention needs to be focused on the detail
of the measurement. As commented by Boutellier and Ullman36 and shown in Figure 16, the level of
detail an indicator has is directly related to the level of motivation it creates in the individuals. As
observed, motivation is highest when the level of detail in the indicator has a medium level. This means
that associates are highly motivated if they have clear goals that show their efforts but still have room for
innovation, risk taking and perform their own process management.
Football without Performance driven Micro management
Level o score empowerment
motivation
Low Level of detail of High
performance measurement
Figure 16. Representation of the level of motivation and the level of detail the KPIs should have, given
the type of process is being analyzed 37
The same authors state that core activities performed in rational drug discovery, scaffold analysis and
DMPK, can be categorized in a transition phase from a product to process innovation. Consequently, they
ensure that, if the indicator used to measure performance has an extreme level of detail, there is limited
room for an individual's initiative and the process arrangement can kill innovation. Boutellier and
Ullman's recommendation in this case is to develop a measurement system that combines process control
with individual's autonomy enabling also a higher level of motivation.
36 (Boutellier, A case study of lean drug discovery: from project driven research to innovation studios and process
factories June, 2008)
37 (Adapted from Boutellier, 2008)
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Along the same lines, another case study analyzed by Boutellier and Ullman suggests that streamlining
activities achieve better results when the organization is process oriented. The four step approach
presented by the authors and shown in Figure 17 mirrors EPP's unit goals. This provides the second hint
towards defining EPP's KPIs: if the aim is to construct reliable operations, selected indicators should
combine profiling data quality with specific speed metrics.
1 38Figure 17. Representation of the steps to create a process oriented organization
Using the above information, an iterative procedure is conducted to create a robust and outlier resistant
statistical method that can be monitored for quick identification of experimental problems39-
1. Interview the Medicinal Chemists to review CTQ's outcome and define which measurements are
understood by the team.
2. Review selected measures and evaluate how each of them explains defined CTQs.
3. Assess ability of selected variables to link different stakeholder's incentives and consider its
robustness and significance in drug research activities.
4. Examine the variables with lab associates and lab heads to find applicability of indicators in day-to-
day operations.
5. Take chosen variables to chemists for a re-check, obtaining defined in step 2. Steps 2-5 are repeated
until general agreement defines ultimate indicators to be used.
6. After a series of interviews with all stakeholders, initial goals were created for each one of the selected
KPIs.
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39 (Gubler, February, 2007)
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Final selected KPIs are separated into two major categories: speed and quality. Figure 18 outlines each
selected indicator into these categories, showing the variables selected for each category and the basic
framework forthcoming analysis will be based on.
Mean of total turnaround time Plate acceptance rate:
- C50 of RC (UCLJLCL)
Range of total turnaround time *R of RCI -C/C ratio
Mean f EP/BIOtimeCompound data acceptance rate:
~AC50 ratio of cmpd (n I /n2)
Range of EPP/BlO timne *#unmasked data points
Figure 18. KPIs selected for EPP's process analysis and performance measurement
A more detailed description of the KPIs is presented in Table 3. In here, definition of each indicator, units
of measure, and calculation procedure are expressed. In addition, each independent variable is identified
by a letter and a number. The codifications will be used in data analysis when relating the outcome of the
process, KPIs, with input variables, X (using the analogy to a function, where y is the result and x the
input: y = f(x)). It is important to mention that the goals from Table 3 illustrate the ideal state (mostly for
measurements of quality that hasn't been tracked this way before) and refer to First Pass Yield (FPY) for
indicators different than time. In other words, a 100% of Reference Compound AC50 means that a 100%
of the data submitted to chemists should have reproducibility of Reference Compounds data (second
column), but internally, the goal is that 95% of Reference Compound's AC50 is within the defined
control limits. If not, the assay should be repeated in order to achieve the goal of 100% of delivered data
with acceptable Reference Compound AC50.
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Table 3. Description of Key Performance Indicators
GOALS
KPI DESCRIPTION UNTS* CALCLTATION teALSInternal/
Time elapsedfrom beginning to end of the activities and
measure: the total length of/a cyle Total time start:
Turnaroundi rimie w hen a chem:t generates a reque:t andnf ishes when
assay data is published For EP? time, cycle starts w hen
the compound is receved in the biolog laboratory and
finishes i hen the data is published
Mean total 12 days
turnaround time (Yl) These times refer to the average of the times in a
- ---- ~days -- T-
Mean EPP particular timeframe 0 days
turnaround time (Y2)
Range total 22
turnaround time Y3) Range is calculated by subtracting the highest time ttdays
observed for a given period from the shortest time days where t-time iperiod
Range EPP ) registered for that same period egmonth 21 days
turnaround dime (Y4)
Flare acceptance Shows the trends for indicators ofthe plate a: an unit.guiding the decision of repeating the pro/dling of/all the %6T 4 (%Y 90% 98%
rare compounds in that particular plate
AC50 value of the Reference Compound, which should be 96% 100%
AC50 of reference within the controllimits, taking allthe data generated from within 3 standard
compound (YS) past assays. Reference compounds AC50 is previousv % deviations of thedefined and evaluated in assay development and expected value
repeatabihty and reproducibility are already known
Robust 7 gives some iformation about typical data 95 98%
scatter and high.low band separation, which is also Nb' I
RZ' of reference relevant for the cume analysis This outlier resistant of compounds
compound (Y6) indicatoris defined as the screening window coefficient * of copon 6being a function of the ratio of the signal window and the
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4.4. Understanding and defining the current state
Even with clearly defined metric systems, sustainability of changes can only be achieved when people
become aware of the reasons for current behavior, so that limitations are surmounted. A broadly used tool
for root cause evaluation is System Losses, where the process is scrutinized looking for 8 different types
of wastes or non-value added activities40: defects or rework, overproduction, over-processing, waiting
time, inventory, transportation, motion, and underutilization of people. Table 4 shows a summary of the
wastes in evaluation and common causes for their existence. Often times, other wastes such as
inflexibility and variability are also considered when realizing process evaluation.
Table 4. Type, definition and causes of the 8
WASTE DEFINITION
Defects/ Work that contains an
Rework error or is not "right" and
needs to be fixed
Extra usage of activities
. to double check but notOver processing adding real value to the
final outcome
Redundant work or too
Over-production much generation of a
product too early in time
People waiting for
Waiting time something needed to
continue or start their
own activities
More materials on-hand
than the ones needed to
Inventory perform any activity in a
given time
Transportation
Materials or people
Motion moving along the process
Under-utilization People are not utilized for
ofper- o improvement or value
of people added activities
waste types defined by Lean
COMMON CAUSES
Processes are not correctly specified or people are not
trained correctly
Non standardize process makes it necessary to double check
Over processing makes a backup in case something goes
wrong
Redundant information
Multiple forms of the same information
Quantities not clearly defined
Process capacity is not known
Poor communication between stakeholders
Process steps are not balanced
Poor coordination between process parts
Lack of understanding of the time it takes for each step
Un responsiveness of scheduling systems
Products or materials are ordered in more amount "just-in-
case"
Process is noisy or volatile so inventory is needed to deal
with unpredictability of activities
Layout is not correct
Multiple unnecessary activities or materials are needed from
multiple places
Lack of standardization makes unclear what materials will
be needed until process starts
Associates do not have the authority needed to decide over
process upgrades and direct decision making
Utilizing the process maps for the CM and the CP, each activity can be evaluated in terms of the types of
wastes. Figure 19 and Figure 20 summarize the wastes discovered in each of the general activities. As
presented, wastes illustrated in each box correspond to all the wastes observed for the sub-activities represent
40 (Helping Science to succeed: improving processes in R&D, 2008)
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by the main one. In this analysis, over-processing waste is used to explain processes that shouldn't be present
or processes that are a repetition of some other process (i.e. saving documents already available or re-checking
data).
PRC SMPEPN MANAG R(1)PROC SO MAN
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Figure 19. Types of wastes observed for each activity in Compound Manger's process
PROCESS MAP-EPP/BIO/COMPOUND PROFILER 1) PROCESS MAP-EPP/BIO/COMPOUND PROFILER(2)
Defectsfrework (Over-processing -Over-production *Waiting Inventory ( Transportatiormotion * Underut of people
Figure 20. Types of wastes observed for each activity in Compound Profiler's process
To define the numeric impact of these non-value added activities in the overall profiling time, value-
added analysis tool is implemented to the diagrams above. Steps that may seem or have been classified as
system losses but are necessary to deliver the profiling data given current process, are classified as value
added. Non-value added steps are definitive activities that are in place justas a response of lack of
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process improvement and, if changed, will directly impact overall performance. The following diagram
sketches process activities over time, splitting value added from non-value added ones for a clear study.
COMPOUND MANAGER
TIME (mins/plate of 14 cmpds)
Prob. TOTAL VA NVA
5 10 15 20 25 3D 35 4W 4S 50 55 W0 S5 70 75 80 85 90 95 10O 105 110 115 120 125 130 135 140 145 205 210 215 220 225 230 235 240
1.CmpdstoLab g 10 5 5
2. Rack Prep. 10 - 10
3. Rack Scan 15 5 10
4.TRT 15 5 10
S. Prep. sorting 15 5 10
6. Auto sorting 5 5 -
7. Problem Solving 5% 0.8 - 0.8
8. Transfer cmpds 10 - 10
9. TRT 10 5 5
10.Update list 5 - 5
11. Data prep. dilution 15 - 15
12. Cmpd prep. dilution 15 15 -
13.Automated DRC 65 65 -
14.Remainder in fridge 5 - 5
15.Plate DRC to fridge 5 5
16. Plate copy 70% 10.5 7.0 3.5
17.Finish data entry 10 - 10
221 117 104
ENon-value added Value-added 53% 6
COMPOUND PROFILER
2. Robot booking 5 5 -
3. DRC sheet r a 10 - 10
5. Enzyme prep |$$ 90% ' 13.5 14 -
6.Enzymeinrobot 90% 4.5 5 -
7. Substrate prep 1590% 2 13.5 14 -
8. Substrate in robot gi90% r 4.5 5 -
9. Incubation 90% 63.0 63 -
Sa-I1a. Het assay 10% 10.0 10 -
9. Get raw data 5 - 5.0
10. Workliot r 5 ' - 5.0
11. Plate reg 10'r - 10.0
12. Prep. Analysis 1
13. Data analysis 9 15 15 -
14a. Cmpd repetition 20% .0 - 40.0
14. Data submission 10 - 10.0
Assay repetition? 15% 33.8 - 33.8
263 129 134
Non-value added Value-added 49%
Figure 21. Comparison of value and non-value added activities in Compound Manager and Compound
Manager's current process
From the figures above, the main conclusions are:
1. Non-value added activities take almost half of the time needed for the CM and the CP to end one
process cycle.
2. For the CM, system losses are primarily due to re-processing and the lack of a better communication
method among associates.
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3. For CP, system losses are mainly due to software and information technology infrastructures, the lack
of associate empowerment to take decisions or review information about compound data reproducibility,
and limited information flow from the chemists to better consider starting concentration when profiling.
Given that activities are not standard and procedures differ even for the same associate when performing
sequential assays, time stamps show the most common pathway with an average length for any given
compound. In the same way, the column of probabilities shows the proportion of the time that the activity
occurs.
When performing the value-added study, it becomes clear that variability in profiling delivery times come
from the lack of procedure standardization. Even with all automation already on place and software for
data analysis, if the process has a high variability, profiling times won't be stable. One of the reasons for
the lack of common work is the high proportion of non-value added activities for both, CP and CM.
These activities deviate people's attention towards process improvement, generating instead a day-to-day
focus in problem solving.
In the next chapters, data is deeply studied and related to current process observations to define root
causes and main focus for immediate improvement.
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5. DATA ANALYSIS
Now, based on the framework presented in Figure 9, Data Analysis is the next step after realizing the
Process Analysis. This section of the project evaluates historic data from the process in order to
understand trends, patterns, relationships, and, most importantly, the impact that each variable has on the
overall observed result. When looking at a process and its resulting data, many variables seem to be
responsible for the outcomes and a common mistake is to try to either control or change all at once. Even
if several factors are involved in the process, patterns can be explained by finding the root causes that
trigger the rest to behave in a certain way. Comprehension and control of these variables lead to
continuous process improvement.
The first step for data analysis is to characterize the current state. To define a lab's performance and
operations, assay demand is the first measure to evaluate. As shown in Figure 22, the number of assay
requests has been changing throughout the months with no specific trend. As presented, the green bar
corresponds to the number of tests and the red bar shows the number of requests that were rejected in a
given month.
Figure 22. Total number of assay requests per month, from January 2005 to July 2009
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When combining the total number of assays with the specific turnaround times for each period, trends
presented in Figure 23 are obtained. Important to notice how overall speed is not directly correlated with
the number of compounds tested. This fact is the main trigger for future data study. In the graph, left axis
corresponds to turnaround days represented by the wide bars. Axis to the right corresponds to total
compounds tested, which are represented by the skinny bars.
Figure 23. Combination of compound demand with turnaround times, from January 2005 to July 2009
Lastly, a summary of EPP/Biology's lab demand for 2009 is summarized in Table 5. When looking at
this data and comparing it to the same analysis for previous years (not presented in this document), a key
observation is that Compounds tested in different assays increase as the project advance in phase. This is
a result of common practice in drug discovery, in order to test compound selectivity. Although, when
observed carefully, data shows how the trend for EPP has been slightly shifted: in the years 2005 and
2006, tests for selectivity were done at later phases, mostly D3. After 2008, and as of October 2009,
selectivity has been evaluated mostly in D2b. This can be observed as a positive trend that will, if pursued
correctly, push forward only candidates that are selective enough, potentially decreasing the decision
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making time in later phases.
Table 5. Summary of selected data for
Total TotalPhase of the tests cmpds
project (# #
DO 409 200
D1 370 282
D2a 1,275 584
D2b 4,687 2,370
D2b-D3 299 1,160
D3 1,909 1,112
D3-CSP 313 162
D4 9 9
DevSupport 6 6
ReferenceCpd 16 14
TOTAL 9,293 4,857
EPP during the year 2009 from January to October
Cmpds tested Average Average
in several time synthesis time
assays (days/test) (days/comp) (a
87 4.95 0.59
52 2.74 0.65
221 7.40 0.19
829 7.65 0.05
43 6.31 0.80
357 6.31 0.13
20 8.07 0.77
0 8.89 26.67
0 9.50 40.00
2 11.63 0.00
7.34 6.98
verage tests
ssays/month)
34
31
106
391
25
159
26
1
_1
_1
774
The purpose of the next sections is to evaluate each one of the Ys defined in the metric system from Table
3 and identify specific root causes (Xs) that control the overall process behavior. Given the variety of
tools and combination of measures used in the process of finding root causes, all following analysis is
based on specific guidelines and tools defined by Novartis IQP. The goal is to provide for each variable a
comprehensive evaluation of the current state, a list of identified root causes and initiatives for
improvement.
5.1. Turnaround time: Mean and range values
The first indicator in the KPI list is assay time, defined by the average duration and the range of durations
for a given period. Response variables 1 to 4 (Yl, Y2, Y3 and Y4 as named in Table 3) represent the
different measurements for profiling time and spread. This combination allows the Biology lab to track
the specific variation of the internal profiling time without forgetting that the time the chemists perceive is
the total time starting with the filing of the request until receiving compound results. To provide a
structured analysis, this section is further divided in 4 main sections: Current state definition, list of
possible root causes, statistical analysis, and process capability analysis.
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5.2.1. Current state definition
When studying historic turnaround times, one of the key challenges is to determine which of all the
possible independent variables from the system is/are the one(s) influencing the observed results. To
overcome this challenge, this section evaluates historic trends of total and EPP/Biology lab's times from
an analytical and statistical perspective.
An indicator used in process improvement to describe the current results in terms of the desired state is
Defect per million opportunities (DPMO), calculated by the formula below:
DPMO = 1, 000, 000 x niuber of defects
number of units x number of opportunities per unit Equation 1
The DPMO value shows the total number of defects or nonconformities that an outcome has, related to
the number of chances the process has to generate a defect. This parameter differs from the calculation of
number of parts defectives or incorrect outcomes when the indicator has more than one possible defect or
a defect can be generated in several activities of the process.
In the case of turnaround time, number of defects is the number of instances that the time measured is
greater than the agreed one, and the number of units is the number of requests that are being considered.
The number of opportunities per unit in this case is 1 given that there is only 1 chance of "getting a unit
wrong" (an assay is either on time or not). The time used as the parameter to define if the request is on-
time or not is 10 days for EPP/Biology and 12 days for the total turnaround time. These two times are the
ones already accepted as the threshold for the EPP associates. Table 6 shows the summary of the results
taking historic data from 2007 to the third quarter of 2009, also showing the percentage of errors
(DPMO+10,000).
Table 6. DPMOs for Total and EPP/Biology lab turnaround time in 2007, 2008 and until Q3 2009
2007 2008 2009
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
N* of defects 766 1,095 925 730 1,175 979 89 258 287 113 127
EPP No of opport. 3,481 3,994 4,661 2,748 2,467 5,166 3,045 3,019 2,833 2,705 2,535
Biology DPMO 220,052 274,161 198,455 265,648 476,287 189,508 29,228 85,459 101,306 41,774 50,099
Percentage 22.0% 27.4% 19.8% 26.6% 47.6% 19.0% 2.9% 8.5% 10.1% 4.2% 5.0%
w/ defects____________
N of defects 791 1,395 1,053 780 1,315 1,001 133 385 390 142 201
Total No of opport. 3,481 3,994 4,661 2,748 2,467 5,166 3,045 3,019 2,833 2,705 2,535
time DPMO 227,234 349,274 225,917 283,843 533,036 193,767 43,678 127,526 137,663 52,495 79,290
Percentage 22.7% 34.9% 22.6% 28.4% 53.3% 19.4% 4.4% 12.8% 13.8% 5.2% 7.9%
w/ defects _______________
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When realizing previous study, some data was not included. This data will not be considered in the rest of
the analysis:
1. Times with zero days in total and EPPIBiology time: Given current process flow, the turnaround time
for assay profiling in the Biology lab has to be greater than zero. In the same way, if the time in the lab
has to be greater than zero, the total turnaround time should also be greater than zero. Data points with
zero turnaround time correspond to requests that did not go through the processes established in the maps
(Figure 13 and Figure 14). Given that those specific activities are the ones under evaluation, these data
points will not give any important insight about the process, although can confuse obtained results.
The reason why it is possible to have in the system zero days is because every compound has to be
manually transferred from one period to another (via TRT). At the end of the process, the software has the
constraint that if the compound is not "in the last step" in the system, the data cannot be evaluated or
submitted. Requests that were not released in the appropriate moment, in order to evaluate the data they
are virtually promoted through steps to close the loop. As commented before, these data points provide no
real evidence of the process length or dynamics.
In contrast, requests with a zero value for the process in the NCA correspond are considered in the study.
These cases correspond to requests that are generated internally by the biology lab when problems in the
process arise. These problems require the compound to be tested again. In some cases, the lab has still
enough amount to perform the test repetition or the chemists provide another vial with a sample of the
same batch in order to decrease profiling time. In either case, the lab does not need material from the
compound hub, reflecting a zero time in this activity. Given that the processes in analysis are the ones in
EPP/Biology, these data points have information that can be useful to evaluate. Later in the project, this
dataset is analyzed aside from the rest of the data, in order to observe trends or specific dynamics when
compound repetition is present.
2. Requests with a total turnaround time greater than 90 days: as agreed internally with EPP's
associates, any request with a time greater than 90 days correspond to data that was not updated in the
system in the correct time and was virtually moved through the departments without reflecting the real
duration in any phase. As discussed with the lab heads and the project heads, no project will wait more
than 90 days for a potency result. This argument demonstrates how database reports are not being tracked
and raises a flag of data possibly not being reliable.
3. Rejected requests: this type of requests is stopped at any point of the process because they present
some error, which could be a typo, a compound requested that is not available, a compound quantity not
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available, etc. Any time reported in the database for received requests is not certain to provide a real
insight about profiling times.
From a first observation to Table 6, it can be observed how from 2007 to 2008 there has been an increase
in the number of requests that were delivered under the expected timeframe (10 for EPP/Biology and 12
for total time). To corroborate that observation, a time series plot of the mean turnaround values over time
is presented in Figure 24.
--- EPP Biology
-n-*Total time
2007 to the third quarter of 2009
From this figure, the observation can be sustained and further statistical analysis is to be performed to
define of the decrease in turnaround times over time is significant. To accomplish this study, a Mood's
Median test is performed and the outcome is presented in Figure 25, assuming that the data from each
population is an independent random sample and the population distributions have the same shape
4 1
.
Mood's Median test was selected given that the data is not normally distributed and Mood's Median test
is more robust against outliers and extreme values
4 2
, which, as mentioned before, are present in these
datasets. In the analysis, the average time for each quarter is compared, using data from Q1 -2007 to Q3-
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41 (Rice, 2007)
42 (Rice, 2007)
2009. The null hypothesis to be proved is that there is no significant difference between the average times
of the quarters.
Mood Median Test: Time in EPP.Biology Lab versus 0-Year Mood Median Test Time in total loop versus 0-Year
Hood median test for Y2-TIME IN EPP/BIO Mood median test for Y3-TOTAL TIME
Chi-Square - 3548.79 DF = 10 P - 0.000 Chi-Square = 3216.46 DF = 10 P - 0.000
Individual 95.0; CIs Individual 95.0% CIs
0-Year N<= N> Median 03-01 -- +---------+------------------+--- 0-Year N<= N> Median 03-01 ---------------- +------------------
01-2007 1709 2274 5.00 8.00 01-2007 1776 2207 7.0 8.0
02-2007 1752 2435 6.00 9.00 02-2007 1232 2955 9.0 10.0
03-2007 4189 2087 2.00 6.00 *1 03-2007 3726 2550 5.0 10.0 *
04-2007 1317 1713 5.00 10.00 04-2007 1199 1831 8.0 10.0
Q1-2008 644 1966 10.00 11.00 *--- 01-2008 579 2031 14.0 15.0
Q2-2008 4856 2362 2.00 6.00 * 02-2008 4561 2657 4.0 8.0 *
03-2008 2436 820 2.00 4.00 * 03-2008 2256 1000 5.0 4.0
04-2008 2422 860 3.00 4.00 0 4-2008 2155 1127 5.0 5.0 *
01-2009 2131 1155 3.00 5.00 C 01-2009 1742 1544 6.0 6.0 *
02-2009 1982 1208 3.00 5.00 02-2009 1566 1624 7.0 5.0
03-2009 1729 1068 4.00 3.00 * 03-2009 1547 1250 6.0 4.0 *
---------- ------------ 
--- - - ----------- 
- --------
2.5 5.0 7.5 10.0 6.0 9.0 12.0
Overall median = 4.00 Overall median = 6.0
Figure 25. Mood's Median test result for Total and EPP/Biology times from Q1-2007 to Q3-2009
Two main conclusions can be derived from this figure:
1. The null hypothesis is rejected, concluding that there is a significant difference between the average
turnaround times for the quarters. As observed in Figure 25, the quarters that present a significant
difference for EPP/Biology are Q1, Q2 and Q4 of 2007 and QI of 2008. From these, Q1-2008 can be
neglected, given that in January 2008 the personnel was changing buildings, so that there were almost no
request profiled during this month. This month can be driving the average value down. One could
evaluate the quarter with no January data, but this is not realized in this project in order to maintain the
data form the database.
In the case of 2007 it can be observed how the efforts the lab has been promoting have generated a
significant reduction, decreasing the average turnaround time of the lab from 5 days in 2007 to a value
close to 3 days in the following year (if Q1 of 2008 is not considered).
2. The spread of the data and the length of the total turnaround times can be explained by the time in the
EPP/Biology lab. It is concluded that the quarters that have significant difference correspond to the same
ones that have a significant difference EPP/Biology lab time: Q1, Q2 and Q4 of 2007 and QI of 2008.
This result shows how impactful it is to improve EPP/Biology operations. Given this trend, future
analysis only consider EPP/Biology times, based on the conclusion that this time is the one that drives the
total compound request profiling time.
With the aim of characterizing the current behavior, basic statistics are calculated for total and
EPP/Biology lab times, and the results are shown in Figure 26, Figure 27 and Figure 28. Once again, it
can be observed that the outliers present in the total request time perceived by the chemists, correspond to
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outliers generated in the Biology Lab, so that, by controlling the time internally in the lab, significant
results will follow.
TOTAL TIME -2008
95% Confidence Intervalsmean I-
60ia 65 70 7 IG 0
Adernee-Darlieg Normality Test
A-Squared 876.71
P-Value < 0.005
Mean 8.9409
StDev 8.5925
Variance 73.8316
Skewness 2.9596
Kurtosis 15.4749
N 13697
Minimum 1.0000
Ist Quartile 3.0000
Medan 6.0000
3rd Quartile 11.0000
Maxinmn 90.00W
95% Confidence Interval for Mean
8.7970 9.0848
95% Confidence Interval for Median
6.0000 6.0000
95% Comdence Interval for StDev
8.4920 8.6955
TOTAL TIME - 2009
0 12 24 36 48 60 72 84
95% Cedndence Intervals
Mean
Moan B
Median 7 7
7.0 7,2 7.4 7.6 7.8
Anderson-Darling Normality Test
A-Squared 585.69
P-Value < 0.005
Mean 7.6871
StDev 6.5194
Variance 42.5022
Skewness 5.6703
Kurtosis 51.9100
N 8073
Minmu 1.0000
1st Quartile 5.0000
Median 7.0000
3rd Quartile 9.0000
Maimurn 87.0000
95% Confidence Interval for Mean
7.5449 7.8293
95% Confidence Interval for Median
7.0000 7.0000
95% Confidence Interval for StDev
6.4203 6.6215
Figure 26. Basic statistics for the total turnaround time, from January 2008 to October 2009
EPP/BIOLOGY TIME -2008
0 12 24 3 48 60 72 84
m em s" * *o* * #40 0 1e
95% Coefidence Intervals
Mean *1
Median =
40 45 5 n g r n R_
Anderse-Daring Nermealty Ted
A-Squared 1212.50
P-Value < 0.005
Mean 6.5733
5tDev 7.9321
Variance 62.9184
Skewness 3.6444
Kurtosis 21.9593
N 13697
Minitum 1.0000
1st Quartie 2.0000
Medan 4,000
3rd Quartile 8.0000
Madnuvm 85.0000
95% Coeeidence Interval for Mean
6.44D4 6.7061
95% Confidence Interval for Median
4.0000 4.0000
9511 Cenfidence Interval for StDev
7.8393 8.0272
EPP/BIOLOGY TIME - 2009
0 12 24 3 48 60 72 84
EU0* 1@, W 410*1e * 4 og
95% Confidence Intervals
Meant
Median ]
4.0 4.2 4.4 4. 4.8 5.0 52
Adersoen-Darlng Normality Ted
A-Squared 762.09
P-Value < 0.005
Mean 5.0287
StDev 6.0697
Variance 36.8413
Skewness 6.6362
Kurtosis 65.5715
N 8073
Minimum 1.0000
1st Quartile 2.0000
Median 4.0000
3rd Quartile 6.0000
Maxhnrn 85.0000
95% Confidence Interval for Mean
4.8963 5.1612
95% Ceefidence Interval for Median
4.0000 4.0000
95% Cenfidence Interval for StDev
5.9775 6.1648
Figure 27. Basic statistics for the time in EPP/Biology lab, from January 2008 to October 2009
Figure 28. Box plot of profiling time in EPP/Biology Lab and total time for each quarter from 2007 to the
third quarter of 2009
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Finally, it is important to observe from the figures above how outliers are still present even when the data
was cleaned before evaluation. This situation shows how the variation of the turnaround times is critical
to the final profiling time, and a strict threshold for outlier definition ca not be established from the
current values in database. This phenomenon is observed from the difference between mean and median
values presented in Figure 26 and Figure 27, and clearly represented in Figure 28, which shows the box
plot surrounded by a dotted line representing the total range.
In conclusion, from the analysis of the turnaround times it can be said that the profiling duration in the
EPP/Biology controls the total duration of the requests turnaround times, not only in length but also in
spread and variation. Even when average times have been decreasing over time total spread has not,
which is one of the reasons leading to the large turnaround time difference mentioned by the chemists
when the research for this project was starting. As a result, focus on EPP/Biology improvement can lead
to an improvement of the overall turnaround compound test duration.
5.2.2. List ofpossible root causes
The brainstorming of root causes is formalized by the 5 Whys procedure, resulting in the Fishbone
diagram displayed in Appendix F. If the brainstormed causes are related to the current variables stored in
the database, the list of possible root causes can be defined as:
- Type of project: it is perceived that projects can have different profiling times, depending on a
particular priority, number of compounds produced, or even interest of the personnel (mostly lab heads).
To analyze this situation, the type of project will be evaluated using type of screening, type of profile,
type of protocol, and target for each specific compound requested.
- Internal vs. external requests: as discussed before when evaluating the profiling times in the lab,
internal requests are observed to have a minor turnaround time than normal requests. In order to define if
this difference is significant, a statistical analysis is performed to compare internal versus external
compound requests. Some of these requests can even be for the same compounds, if the trigger for the
internal requests is the need for a profiling repetition. For this analysis, requests are separated into
EPP/Biology internal requests, EPP/MCH for requests from the chemistry lab within EPP and others,
which will correspond to any requestor out of EPP projects.
- Phase ofprojects: another variable that can affect the turnaround time is the phase of the project. It is
understood that projects in some stages are more important than others and may have priority when
profiling. To evaluate this situation, requests are divided in the phase established in the system when the
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compound is submitted. It can be the case that a project, overall, is in a phase but a compound is
submitted to an earlier stage of the same project. This is present when second generation of compound is
developed in order to have backups for future analysis. This separation of compounds by phase will
reveal is the compounds that are moving towards later phases are really prioritized in the profiling
process.
- Location: there is the argument that having a centralized profiling process in Switzerland for other
locations in the world introduces variability and longer lead times to the total length of compound
profiling. For EPP some projects are driven by the chemistry in Massachusetts, USA, and the profiling is
realized in Basel, Switzerland. One of the thoughts is that these data points should not be considered
when calculating the total turnaround time, given that the biology lab cannot control shipping times. This
scenario will statistical evaluated analyzing the profiling times for each location.
5.2.3. Statistical Analysis
With the intention of reducing the impact of outliers in the analysis, only data from the second quarter of
2008 to the third quarter of 2009 is considered. Also, each variable will be evaluated towards
EPP/Biology profiling time, referring to the conclusion stated before that outliers and total process
performance are described by EPP/Biology lab's behavior. Lastly, Minitab is employed for the statistical
analysis and Mood's Median Test is used if not stated otherwise.
The results obtained for the Mood's Median Test are presented in Appendix G. As observed, the
screening types with codes As2, Se16 and Se4 are the ones that present a higher variability. Even when
the turnaround times for these screening types can be affecting the biology lab performance, only Se4 and
Se5 can be said to be statistically different, given that the confidence intervals for all the rest overlap at
least at the lower values.
The second statistical analysis is with the protocol type, which is separated only in two categories:
primary and secondary. Primary screening is the first screening that a compound needs and is realized to
obtain a rough potency value. The only question to be answer with this analysis is if the compound is
active or not towards certain target. A secondary screening is necessary when comparing between
different scaffolds or compounds within the same family, so the exact values become critical.
Observing the data Appendix G, clearly secondary screenings have significantly higher profiling times
than primary screenings. From a first thought, this difference can be perceived as coherent with the
process given that secondary screenings can be understood as needing more time to obtain specific
potency values. This conclusion is not correct. Going back to the process maps, it is observed that the
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activities are the same for any compound, independent on any variable that is been analyzed here.
Instead, a root cause analysis shows that longer times in secondary assays are given by the plate
optimization. With the current layout in the biology lab, each assay plate has a maximum of 14
compounds. In primary screening, many compounds are profiled to observe trends among scaffolds and
choose from a broader selection of possibilities. In the other hand, secondary screening is performed
under a more strict compound structure, having a less number of compounds produced per unit of time. If
the usage of assay plates is optimized, secondary compound will be waiting longer for more compounds
to come in order to fill the plate, which promoted longer lead times to this profiling type.
The last indicator is profile code that reflects the target type and enzyme present in the assay. For this
analysis, it is concluded that there is remarkable different between values, not only in the average times
but also in the spread of those periods. As shown in the fishbone diagram, most of the differences in
profiling speed come from the lack of standard procedures among lab technicians, which is reflected in
the profile code too. This result shows, once again, the effect of non-standard profiling schedules for all
the projects and assay panels.
Interesting results are obtained when assessing the impact of internal versus external in Biology lab's
profiling times. As shown in Appendix G, requests that are generated internally by the lab associates have
a significantly lower turnaround time than requests from EPP/Chemistry lab or other Disease Areas. This
behavior is generated by the fact that internal requests are due to either internal error so or a particular
compound need. In both cases, is in the best interest of the direct associate to quickly analyze the
compound. In either case, the compounds are treated preferentially in the process, resulting in a
significantly lower profiling time. Even when times in NCA are zero for these compounds (meaning that
at least they have 2 days less) the difference is still significant and even more than 2 days, probably
showing the minimum achievable time in the internal process of the lab.
Continuing with the analysis of internal versus external requests, time lengths for requests that come from
other Disease Areas are significantly higher than those from internal requests, and have much more
variation than internal or MCH's ones. This trend points an area for improvement: scheduling is currently
not showing standard basis, but a preference mode. Further analysis, out of the scope of this project,
should be realized in order to observe the factors affecting this mode of operation.
With all above analysis, it can be concluded that both, internal and non-specific EPP project requests are
shifting the measured turnaround times towards un-real values. In order to have a more standardized and
controlled process, systematic procedures need to be in place so that any request is delivered within
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specific timeframes, in order to push overall drug discovery length when referring to protease targets.
Finally, when implementing a metric system, times should be separated to observe this type of trends and
dynamics in the lab, to have real and sustainable benefits.
Now profiling time will be evaluated towards the project phase. Following the same procedure with
Moods Median test, it is observed the higher the phase the more spread the turnaround times have. It is
interesting how; particularly lead candidate, D3 and D4 phases have significantly longer turnaround
times. Concern may rise also when observing the length and spread of compounds for projects in D4.
Deep analysis of root causes and interviews with stakeholders reveal how compounds that go into more
advanced phases are usually more potent than the current process is set for. Because of this, most of the
compounds that come into D3 and D4 phases are profiled and then, after observing that they are so potent
that IC50 cannot be determined from the graphs, the compound is further diluted and the IC50
determination is repeated. This procedure not only slows the entire assay speed, but also consumes
materials and introduces the repetition that was analyzed in previous sections and defined in the process
maps. This situation is also considered in the value-added analysis shown in Figure 21, as the probability
of compound repetition. Further recommendations will address this limitation of the current flow of
activities.
Lastly, location is evaluated in profiling times. From Minitab's output it is concluded that the work with
the US is indeed increasing the total turnaround times with no difference for the profiling time within the
lab. As noticed from the same Appendix, average values for the US increase from three to nine days when
shipping periods are considered. Even when this may seem as a disadvantage, the total number of
compounds profiled in Switzerland is significantly higher compared to the rest of the world, so that their
impact is not really substantial. If cross-country projects are to be increased, this is the best time to
optimize Switzerland's main procedure to ensure a steady and predictable profiling timeframe for any
country, considering shipping times.
The final analysis is derived from the interviews with all stakeholders, who show concern when thinking
on implementing changes to the process, given that they support about 170 programs Novartis wide. The
following Table shows a Pareto analysis of all the programs.
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Table 7. Pareto evaluation of the programs supported by EPP over the last 3 years
PROGRAM Cumulative % of Average of NCA Average of EPP/Biology Average total
annual requests time (days) time (days) time (days)
e12 18.2% 4.2 15.9 20.1
a19 31.0% 2.7 16.0 18.8
a26 42.7% 4.5 10.2 14.8
e4 50.5% 2.7 10.8 13.5
c13 56.3% 2.9 5.0 7.8
d12 61.9% 2.7 4.3 7.0
c14 67.3% 2.9 12.3 15.2
f6 70.5% 3.2 14.8 17.9
d2 73.5% 2.7 8.7 11.4
x 75.9% 2.9 15.8 18.8
C1O 78.2% 3.5 11.0 14.5
f 80.3% 4.8 10.2 15.0
It can be concluded that from the 172 programs supported by EPP/Biology lab, only 18 programs account
for 80% of all the activities. Also, it can be observed that the time in EPP/Biology for 9 out of the 18
programs has an average equal or higher than 10 days, which means that, even if on average the total
profiling times on the biology lab have an average of 6 days, half of the programs that account for the
80% of the requests will perceive an unacceptable turnaround time (i.e. higher than 12 days). This shows
again how process improvement can be obtained just by focusing on the core activities in the lab, and
when standardized and controlled processes are in place, all current outliers or non-common assays will
follow the optimal trends too.
5.2.4. Process Capability study
This study compared the process to a specific goal and its consistency around the average performance.
This evaluation is employed to assess the ability of a process in meeting expectations and observe
changes that have to occur in order to improve it. In the same way, when tracked, process capability study
is an accurate and easy way to study the impact that changes have in the overall KPI in this study.
The indicators used to define the capability of a process are Cp, CPk, Pp and Ppk. The equations to
calculate these indicators are:
USL - LSLCp 6s
6s Equation 2
Cpk USL - x x -LSL3s M 3s Equation 3
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6s
USL- x x -LSL
Ppk=Min( 3s 3
Equation 4
Equation 5
While Cp and CPk, known as capability indicators, show the ability of the process to meet goals and its
trend around the mean, Pp and Ppk extrapolate the behavior of the system in the future based on the
observed noise and trend in the present. The latter are known as process performance measures. In other
words, Cpk gives information about the capacity of the process to meet certain requirements in the
present, using a calculated standard deviation from a short period (usually 50 data points in a shorter
period of time, i.e. days), while Ppk extrapolates current noise to forthcoming scenarios (the same 50 data
points but larger timeframes, i.e. months) 43. Both are commonly used depending on the aim of the study.
A big advantage of this type of analysis is that it permits the specific study of the noise and stability of a
process in a really simple manner. The following figure shows the different scenarios of process stability.
Stable Process
Stable Variation, Unstable Mean
Unstable Variation, Stable Mean
Unstable Variation, Unstable Mean
Figure 29. Examples of process stability trends"
In the same lines, by looking at the trends in a Control Chart, common and special cause variation can be
separated and actions can be focused on the real limitations of the process. Knowing the specific process
noise that can come from equipment, methods, purity of compounds, etc, actions can be taken when
process outcomes have un-expected and out-of-control patterns in the results. The final goal of this
43 (Novartis Technical Operations)
44 (Adapted from IQP internal presentation: Process Stability)
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analysis is to achieve a state were the process is in control and any abnormal behavior can be observed
and addressed promptly.
Process capability study for turnaround times is realized using Minitab's non-normal data analysis tools,
utilizing data points from Q1 -2008 to Q3-2009. The complete output of Minitab's Capability Analysis is
presented in Figure 30 for EPP/Biology times.
Process Capability Sixpack of EPP/ Biology time (2008-2009)
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Figure 30. Results from the Capability Analysis for the process in EPP/Biology Lab
Starting with EPP/Biology turnaround times, when combining the data distribution presented in Figure
27, the Capability Histogram in Figure 30 is obtained. As noticed, a significant portion of the data is
under the 10-day limit but some outliers are skewing the final average turnaround result to the right
(towards higher turnaround times).
Looking at the Xbar and S Charts in the left of the figure, it is evident that, even when upper and lower
control limits (UCL, LCL respectively) are calculated based on the data and seem to have ideal values,
because of process instability, only few data points are within 3 standard deviations around the mean and
only 2 months in the 2 years are within the boundaries of standard deviation. The explanation for these
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results is given again by the influence of the outliers: a large number of low times (represented mostly by
internal requests considered in the turnaround time) pulls down the mean, while unexpected high
turnaround times provide noise to the outcomes. As a result, the mean value is close to the goal of 10 days
(8.48 days as shown in the chart) and control limits are tight to that value, while most of the dataset is out
of the range. Values marked with red in these charts are the result of the testfor special cause variation,
which mark points that present a distinct trend and should be analyzed. Given that most of the data points
are marked, it can be concluded that noise in the process is causing the unpredictability and instability
perceived by the chemists.
The only analysis left now is the process capability and performance. As observed, Cpk and Ppk have
values of 0.07 and 0.06 respectively. Given that these values are significantly lower than 0.5 (theoretical
used threshold) it is demonstrated that special and common causes for variation can be separated until the
process is stabilized.
As a general reference, Figure 31 shows the results of the same capability study discussed before, but the
time for the total turnaround times. As observed, findings are comparable to the ones presented for
EPP/Biology time, reinforcing once again that the Biology lab generates the total profiling time variation.
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Figure 31. Results from the Capability Analysis for the total process
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Finally, one last comment has to be made about the results obtained when outliers are considered. When
setting a boundary for the data outliers, ideal case is that the dataset presents a clear gap, so that outliers
can be are clearly observed and the threshold can be established with confidence. In contrast, EPP historic
turnaround times cover all possible durations; therefore 90 days seemed an arbitrary decision. If all data
points are evaluated, capability analysis calculates UCL and LCL of 18.6 and 0 for EPP/Biology times
with a mean of 5 days. This result strengths the need for reducing process noise before concluding the
effect of changes in the final process result, which can be achieved by standard procedures and the
utilization of a measurement system.
In conclusion, turnaround times in the EPP/Biology lab deceased from an average of 8 days in 2007 to an
average of 4 days in 2009. To define a significant difference between these values, internal requests
should not be considered, thus increasing the mentioned turnaround time. Turnaround times for the entire
loop are affected and defined by the length of the profiling time in the biology lab, and are characterized
by a high variation. Variables that are affecting turnaround time's dynamics cannot be strictly defined
until process noise is separated from special cause variation.
5.2. AC50 of Reference Compound
Shifting to the quality side of the established KPIs, the first metric is plate acceptance rate, which
represents the assay plate integrity. This measurement is realized by tracking the reference compounds
(RCs) in the plate and relies on the extrapolation of RC's integrity to the rest of the compounds in the
plate.
As commented in prior chapters of this project, the extensive number of available variables for each
compound inhibition curve has lead to the usage of different metrics by each lab associate, without
comparing data consistency across assays. This lack of cross-assay review creates the data variation
perceived by chemists and decreases the reliability in the lab's profiling data.
The first sub-class under the quality metrics shown in Figure 18 is RC AC50, which compares expected
RC potency with the result in each plate.
5.2.1. Current state description
During the last few years, EPP has been implementing several software changes with the objective of
improving data collection and analysis. With these changes, many procedures and measured variables
have been changing also, limiting data comparability. To provide an analysis with recent data and in
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comparable conditions, data used in the quality analysis correspond to the period between January 2009
and October 2009.
When analyzing historic data from RC, some surprising observations are identified:
- 8 RC are used in 83% of the assays: From the data in analysis, 83% of the assays used 8 RCs out of
the 27 listed. Figure 32 has a descriptive Pareto chart of the result.
Several advantages can be mentioned from the use of the same RC across assays, aside from cost benefits
of buying higher quantities of a reagent. Having the same RC can help to better understand how the
specific enzyme and/or substrate affect the observed compound potency, helping also to understand
specifics about the target in evaluation. Also, when improving the process, clear changes in most of the
assays can be achieved when focusing only on these 8 RCs.
700 100%
90%
- 80%
0 500 70%
400- -60%
50%
300 40%
200- 30%
20%
- 10%
0 -
- 0%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2122 23 24 25 26 27
Compound code
Figure 32. Pareto chart for RC usage
- 20% of the RCs have repeated tests: this observation reveals the yield of the current profiling process
and is related to the previous observation of assay repetition for compounds in D3 and D4. A root cause
evaluation to understand the reasons for this 20% is performed, finding that 95% of this current 20%
repetition rate is due to the presence of highly potent compounds, which need a second or third dilution
for AC50 determination.
- 4 RC are notproperly identified as such: When looking at the number of data points for each
compound, 4 compounds appear to be used as RC but are not being tracked as such, nor have control
limits to define plate integrity. If a compound is not defined as RC, even if the AC50 is manually checked
for every assay, specific changes or trends in RC are not detected and plate validation is constrained.
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Also, given that most of the assays share the same RC, any information on outliers or peculiarities with a
specific compound batch can become beneficial for several other assays too.
- Some of the UCL and LCL definedfor RC can be improved: Observation of particular trends of RC
over time and its comparison towards the control limits established in the database shows that these limits
are not constantly reviewed and/or updated. First, when considering each AC50 data point obtained for a
particular assay plate, data shows that 48% of the RCs have no defined control limits, affecting about
12% of realized assays. This means that, for 12% of the independent assay plates, the RC used had no
quality control limits in the system. It cannot be said that the values of the RC are not evaluated manually
for these compounds or are incorrect, but is evident that these compounds are not being automatically
checked.
Using the same dataset, 2% of the AC50s are below the LCL and 5% are higher than the UCL,
representing a total of 19% of assays that fail the RC quality check. All the data for the compounds
present in these assays was submitted to the chemists, meaning that chemists received data with unknown
quality, which is one of the reasons for the perceived data quality variation by the chemists. Figure 33
graphically shows a summary of all above-mentioned results.
S< LCL; 2%
> UCL; 5%
SOK;81%
UNo control; 12%
Figure 33. Distribution of RC AC50 with respect to the control limits in the database, from January to
October 2009
A more in depth analysis shows that 97% of the assays without a control limit correspond to the new plate
layout recently established, which means that assay reproducibility and repeatability was not realized
before starting compound profiling. Even if new layout can change behavior of the RCs, leading to a
different AC50 from the one in the database, at least historic data could be used as a first approximation
to define plate acceptance. This situation will be discussed later again when identifying root causes.
- 65 -
- Range UCL to LCL is too highfor 65% of cases: Given that the same RC is used in several assays but
the conditions of the assay can lead towards different control limits, for the timeframe between January
and October 2009, there are 144 different combinations of RC-assay. One conservative rule of thumb in
this type of profiling is that a difference greater than 10-fold from one AC50 to the other is considered
significant, meaning that, for repeated assays, if the final AC50 of a compound is in a 10-fold range
(higher or lower), one could argue that the method is valid and any difference is explained by target and
assay condition normal variability. This rule implies that any accepted value for a RC should also fall in
this 10-fold window, which also implies that the ratio between UCL and LCL should be 10 or less. When
analyzing the range established for the combination RC-assay it is observed that 65% of the RC-assay
combination, have a ratio greater than 10. Figure 34 shows all the ratios stored in the database and the
corresponding usage distribution.
UCL/LCLratio
Figure 34. Distribution of UCL/LCL ratio for the total RC-assay combination used from January to
October 2009
Even though most of the ratios are in fact 10, greater values should be clearly explained and agreement
among all project teams should be present. Given that RC control limits are the first approximation for an
evaluation of assay plate data quality, clear conditions and relation to assay conditions is key for future
improvements.
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5.2.2. List of possible root causes
After all above results, possible root causes for the encountered situations need to be listed. Appendix I
presents the fishbone for root cause analysis, evaluating the limitations in the control limits and RC AC50
constant check. From it, the list can be reduced to:
- Novelty of the assay: When an assay is new and the RC is new to the platform, no historical data can be
used to define the range of expected potency. Depending on the case, some assays are key to a project and
its quick development is critical, so that the project team decides to start compound profiling without
specifically knowing data for the RC. In some of these cases, ranges are not introduced or, if so, high
ratios characterize the control limits. Over time, many of these initial values (or lack of values) remain for
the entire length of the project campaign, and is the explanation of the observed 95% of the new plate
layout without RC limits definition.
Statistical analysis of this factor will not be realized explicitly, given that there is not a direct variable
saved in the database that relates the assay plate name with the phase of the compounds in evaluation.
Also, it could be the case that, for a particular assay, the assay plate contains compounds from different
projects at different phases so that straight comparison can lead to misinterpretations. As an
approximation to observe the effect of knowledge curve in assay performance, experiment date will be
used as the independent variable.
- Non-standard procedures: As discussed before in several sections, lack of standard procedures among
lab associates also affects the review of data quality. In this case, CPs use different software indicators to
validate the assay creating noticeable discrepancies when reviewing consistency among assays. The
independent variable to study in this situation is operator.
- RC out of range is observed when assay is finished: Because actions in the current procedures are
reactive, a RC is known to have an AC50 out of range when the assay has been already completed. Most
of the times, the assay data is kept and actions are taken for future assays maintaining the wrong value in
the database.
Along the same lines, RC aging can only be observed if data is manually stored and plotted. When having
an out of range result, what the associate observes is just that specific data point. The result can be due to
aging of the compound, a perturbation to the whole plate or a factor that affected only that specific well.
Given the urgency of assays, equipment booking schedules and profiling priorities, most of the time a RC
out of range is not a clear-cut decision to repeat an assay.
To evaluate these dynamics, the experiment date will be used as the independent variable, which will also
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show the trends of the RC and permit clear observation of batch aging.
In the same category, another important analysis is the determination of batch-to-batch differences, when
enzyme and/or substrate batches are changed. The database contains each of the batches used in every
assay, so that a statistical evaluation of their differences can be realized, if the RC-assay combination had
a change in the time of the study. Further analysis of the possibility for this study is discussed in the
statistical analysis section.
- Error in the robotic systems: In this case, errors can be due to specific equipment failure or interaction
between substrate and enzyme that interfere with the readouts. To distinguish between a robotic defect,
pure variability of the readouts or an error carried out form the beginning of the assay plate generation the
following variables are selected: readout timestamp, experiment time and assay plate name.
5.2.3. Statistical Analysis
A thorough statistical analysis for RC AC50 variation requires a separate evaluation of each of the 144
RC-assay combinations, considering in each case all the independent variables listed as possible root
causes. Given its complexity and considering that 8 RC account for 80% of the assays, the statistical
analysis is realized for these 8 compounds and the most significant assay configuration they represent.
Results for particular discussions will be provided and the rest of non-published statistical outcomes will
be mentioned and discussed.
Following the same procedure as the one for turnaround time evaluation, the effect of each of the
mentioned independent variables on the RC AC50 is shown in Appendix J.
As observed, AC50 of RC varies significantly with the experiment date, which is actually a surprise. Even
when non-controllable conditions may be affecting the resulted AC50, a significant variation of the RC's
AC50 will potentially be related to a greater instability in the resulting AC50 of the tested compounds,
given that RCs are usually the most potent compounds present in the assay plate. These types of trends
are useful to observe in order to define which the days that have more variation are and to find root causes
to eliminate result's fluctuation.
Even though the difference is significant, direct comparison with the control limits will show if the
difference is enough to discard the data from the entire plate. In the next section, a process capability
study will address this direct comparison.
The next variable evaluated is operator. As noticed, the effect of the operator can be significant and, as
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expected, different for different assays depending on the operator's expertise and familiarity with the
protocol. A lab associate usually owns a specific assay, so these differences are not an issue. If help
between associates is required, it is important to measure the impact of that change in the final results, so
that training and/or procedure analysis can be done before the temporary take-over.
Interesting results are derived when deviations from different substrate batches are analyzed. As noticed,
some batches can insert an additional variation to the potency results, such that the final outcomes cannot
be compared. This kind of evaluation is key before starting to profile so that batches can be characterized
and disregarded before affecting the overall project data. Also, if needed to employ a substrate batch that
is known to cause different data, measures can be applied to convert resulting data or compare in a
relative scale results obtained with this batch with the other batches.
Readout timestamp also appears to have a significant impact in the AC50 obtained for RCs. As shown in
Appendix J, AC50 values differ significantly depending on the time the readouts were performed, which
could correspond to either a variation of the equipment or a particular situation with the assay conditions.
As observed, for both revealed analyses, different timestamps have different statistical characteristics (i.e.
mean, confidence intervals), which show that differences come mostly from equipment noise. This type
of un-controllable noise adds variation to the process (common cause variation), and will be observed
when evaluating the process capability.
Another compelling discovery is how the time a particular experiment is performed affects significantly
some assays. As presented in the statistical analysis results, C1 and C2 behave comparably at any time of
the day, while analyzed assays for C4 and C5 have a significant difference with the experiment time.
Once again, it is important to mention that these results can be due not only to differences in the time
itself but related to other specific variables not addressed in the analysis. Because of this, it is important to
evaluate regularly the obtained RC's results so that specific causes of variation can be identified and
corrected promptly.
Lastly, the assay plate name is evaluated. This variable is a consecutive number that provides not only an
insight of the changes in results over time, but also from plate to plate, even if several plates were tested
at the same time. As concluded in the statistical output from Appendix J, variation from plate to plate is
related to the assay and could be linked also to specific perturbations due to robotic system defects or
assay conditions that occurred only for that particular test. Once again, this reinforces the need for a
protocol to continuously evaluate assay performance so that real root causes can be immediately defined.
In conclusion, as in the case for turnaround times, most of the variables studied affect one or more of the
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RC-assay combination analyzed. Is evident that the noise of the process is so high and the interaction
between variables so weakly understood, that specific root causes are hard to define though a statistical
analysis.
5.2.4. Process capability study
The last evaluation for AC50 of RC is the capability of the process to replicate its value in separate
assays. As an example, Figure 35 presents the study for C1 in assay 62-1. For this particular RC, most of
the values fall into the upper and low control limits established in the system, as observed in the
capability histogram in the right of the figure. It also underlines again the importance of a graphical data
representation when aging of the RC batch is to be forecasted. Looking at the Xbar chart in the left of the
figure, constant increase in AC50 over time is clear, and with the tools in place, batch changing can
become proactive. In addition, is evident how after a batch change, AC50 of RC drops to a value within
the expected range.
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Figure 35. Process capability analysis for C1 in assay
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5.3. RZ' of Reference Compound
5.3.1. Current state definition
As described before, parameters that do not contain any information about data variation are less
appropriate for assay quality evaluation. As a result, robust Z' was defined as one of the most important
variables to determine assay plate quality control and assay performance4 5. This indicator combines the
signal amplitude and the variability of the assay, directly relating statistically significant thresholds of
activity for compounds.
Because high RZ' values do not guarantee that an assay is valid or that the data is reproducible, this KPI
is used in this case to monitor trends in time, evaluating assay consistency. Given that RZ' values are
assay specific, these values are analyzed in the same way as the parameters for AC50 of RC. Considering
data for the two most used RC, current state is shown in Figure 36.
Summary for RZ prime for RC 1 in assay 62-1
Andersa-Darg Normality Test
A-Squared 0.44
P-Value 0.277
Men 0.94083
Stoev 0.02688
Vanence 093872
Sk -048210
Kur1tss 0.247148
N 81
- Minmu 0.85366
___________________________ 
1st00.9880 0.9258
0.9 088 08 002 0N4 0h 0.98 Medan 0.93577
3rd Quarde 0.96134
Maximm 0.98673
95% Confidence Interval for Mean
0.93488 0.94677
95% Cofldenoe Interval for Medan
95%3 Confidence Intervals 0.31 0.94977
95% Coadence Iterval or StDev
002328 0.03180
0.9350 0.9375 0.9400 M.9425 0.945D 0.9475 D.9500
Summary for RZ prime for RC 4 in assay 90-1
AKersoDring Normaty Test
A-SqLred 10.11
P-Value < 0.005
Mean 0.9330
StDev 0.05850
Varance 0.00342
Skewness -2.09916
Ktoss 3.41128
N 81
Mviimum 0.72659
1st Quartie 0.89798
a.75 0.80 0.82 nas oMedan 0892522
3rd Quarde 0.93614
Maimumn 0.95644
95% Confidence Interval for Mean
0.89037 0.91624
95% Confiderce Interval for Moea
95% Confidence Intervals 091880 092742
95% Cniece Interval for Stev
-. 05067 0.06921
0.9 0.90 D.91 0.92 0.93
Figure 36. Basic statistics for current state description for selected RCs
It is important to observe that monitoring of RZ' is vital to characterize each particular assay and to define
from there also how variable is it over time and how normal assay variability will affect the final potency
of compounds tested. Also, an evaluation of this indicator can show, when combined with the rest of
selected KPIs, variation produced by intrinsic assay noise from other direct special cause variations.
With the aim of expressing the variation between assays Table 8 presents basic statistics for 12 assays,
which correspond to about 50% of realized tests for the timeframe in evaluation. These values reinforce
the prior statement that characterization of the profiling test variation can be clearly defined by RZ' and
that RZ' tracking has to be done on an assay-to-assay basis.
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45 (Gubler February, 2007)
Table 8. Basic statistics for RCl
Assay Code
19-1
62-1
88-1
89-1
90-1
91-1
41-1
62-2
39-1
38-1
55-1
54-1
5.3.2. List ofpossible root causes
Because all the possible factors that may cause RZ' to vary out of the expected range were listed also
when evaluating root causes for RC AC50, the fishbone analysis in this case leads to the same output as
the previous section's. The list of root causes is reduced to the same ones mentioned earlier as novelty of
the assay, non-standard procedures, RZ' out of range is observed when assay is finished, and error in the
robotic systems. For the statistical analysis the same independent variables are considered: experiment
date, operator, substrate batch, readout timestamp, plate group name, experiment time, and assay plate
name.
5.3.3. Statistical Analysis
It is not surprising to obtain identical results as the ones presented for AC50, when evaluating the
significance of independent variables on RC's RZ'. If potency of RC is significantly affected by the
variables described, RZ' has to be also affected in a similar manner.
Even though RZ' and AC50 of RC are equally influenced by assay variables, their study and tracking is
still beneficial when validating assay plate data. With the current data, it is concluded that the noise of the
process is limiting real definition of significant variables. If special and common cause variations are
separated in the future, individual analysis of RC AC50 and RZ' can be helpful when determining
specific reasons for results variation.
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in different assays performed from January to October 2009
Mean Range SdDev
0.8935 0.1363 0.0332
0.6627 0.0091 0.0052
0.9491 0.1086 0.0244
0.9077 0.2291 0.0508
0.9023 0.2299 0.0537
0.8632 0.4358 0.0898
0.8554 0.4605 0.0671
0.6627 0.0091 0.0052
0.7682 0.4034 0.1149
0.7144 0.4226 0.0996
0.8894 0.1843 0.0468
0.9085 0.1301 0.0335
5.3.4. Process capability study
As usual, process capability diagrams allow a simple and straightforward evaluation of the trends and
historic behavior. Figure 37 presents the results for two selected RCs. As observed, this study confirms
that each assay will perform on a different RZ' window and specific control systems should be developed.
For the RC-assay selection shown in the diagram, RC 1 can be characterized with a more stable and
generally higher RZ' than RC 5. In the same way, RC 5 in assay 70-1, can be described by a more
variable RZ', which can be part of the intrinsic noise of the assay. Track of RZ' can give insight to assay
performance and provide additional information when in doubt about resulting data.
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Figure 37. Process capability study for selected RC-assay combination
5.4. Remaining KPIs
The AC/NC ratio for plate acceptance, AC50 of compound ratio, and number of unmasked data points for
compound data validation are the remaining indicators to evaluate. Because none of these variables are
currently calculated by the software or tracked by the lab associates, the analysis cannot be performed.
Even though, based on literature and lab's personnel experience, it is recommended to add these variables
in future metrics to study compound data quality.
5.5. Observations from data analysis
From the analysis of all KPIs, it can be concluded that the current process presents a high and random
variation that limits strict root cause determination. The statistical analysis showed that most, if not all, of
the independent variables have a significant impact in the result outcome, which demonstrates that the
intrinsic noise of the process (common cause variation) is being influenced by a series of unknown special
cause variations. The limitation of not being able to discern between special and common cause variation
is that trends cannot be improved, leading to unpredictable data patterns.
In order to develop specific process improvements thee following steps are recommended for
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EPP/Biology lab to follow:
1. Establish a routine of monitoring recommended KPIs for each assay, with the goal of having more data
points to increase the quality of the statistical analysis.
2. Prioritize assays given their impact on particular projects and/or the amount of compounds profiled
over time. Select one or two projects to focus on in future improvement.
3. Perform a root cause analysis for results out of the expected limits, increasing the feedback to the
process. This step will increase learning, not only of cause and effect dynamics but also of specific areas
to implement in process controls.
4. Make changes to the process in order to adjust for the recognized causes and monitor the impact of the
performed changes over the outcome. Continue with different variables until expected process behavior is
obtained.
These four steps are iterative, so that, after improving certain assay, loop can be started again with a
different assay, incorporating also learning from previous improvements.
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3. CONCLUSIONS AND RECOMMENDATIONS
6.1. Overview of Results
Through out the previous sections, process and data analysis have described the current state for
EPP/Biology's processes, have evaluated the weaknesses and strengths of the utilized tracking methods,
and have shown the variables that drive process behavior. Conclusions from all these studies can be
integrated to provide a list of areas for improvement and their impacts on measured results.
First, it can be concluded that the initial hypothesis of the project has been confirmed. As in section 3.1,
the hypothesis stated that focus on providing chemistry with a potency value, without further analysis of
the procedures or even of the quality of the data, has limited sustainable process improvement. As
observed from the analyzes, constant technology upgrades and equipment changes, even when providing
some decrease on profiling times, have promoted most of the NVA activities in CM and CP's thus
limiting time available for continuous improvement. In the same way, these constant upgrades in
technology have created a lack of standard procedures, which have impacted the stability of profiling
times, and predictability and repeatability of potency values.
Second, it is important to reinforce that, even when focus on turnaround times can boos process speed,
real root causes have to be addressed in order to achieve real improvement. All the concerns from the
chemists and the biology lab associates are related to the lack of a common system that facilitates
profiling, tracking, and data revision.
Lastly, from the statistical analysis of response variables with respect to possible independent factors, it
became evident how the constant equipment upgrades and the lack of common methodologies have
incorporated noise to the process, to the point where common and special cause variation cannot be
differentiated. In order to have a correct process control, activities need first to have known patterns, so
that special causes can be observed and resolved.
In order to create a sustainable improvement, it is important to maintain the current inertia towards
process upgrade while adding control and tracking methodologies. Current momentum is good, and is
important to keep it alive, but it is also necessary to add some control to observe the impacts these
changes have on the final outcomes. The recommended metrics were listed and evaluated in section 4.2
and are summarized in Table 9. This table also shows the direct benefits of implementing these variables.
- 76 -
Table 9. Summary of suggested KPIs and their benefits
Area ofKPI Current state Area Benefitsimpact
Mean total Available, not Effectiveness / Evaluate impact of results and changes in the overall
turnaround time tracked efficiency loop time perceived by the chemists
Mean EPP/Biology Available, tracked Effectiveness / Define improvements in the highest portion of assay
lab turnaround time efficiency profiling duration
Range total Available, not Effectiveness / Observe outliers and evaluate root causes to improve
turnaround time tracked efficiency the overall compound cycle
Range EPP/Biology Available, not Effectiveness / Observe EPP/Biology lab's outliers and evaluate root
lab turnaround time tracked efficiency causes to improve internal processes
Available, tracked Efficiency / Define strict control limits that help explain RC out of
AC50 of RC (not tracked over range leading to a better understanding of the assay's
time) data quality biology too
Available, not Monitor normal assay noise window to assess
RZ' of RC tracked Data quality abnormal behavior and plate validation
. Can be calculated, Dt li Track assay's potency range for plate validation and
AC/NC ratio not tracked aa quality identify special cause variation
. Can be calculated, Efficiency / Examine cmpd's repeatability to identify abnormal
AC50 of cmpd ratio not tracked data quality values or intrinsic assay performance
Number of masked Recently Classify the quality of cmpd's AC50 curve given the
data points incorporated, not Data quality correspondence of data points with curve fittingtracked
6.2. Recommended areas for improvement
In a more detailed manner Table 10 recommends specific changes at different stages in the future in order
to achieve expected benefits. The table summarizes the areas to focus on, along with the actions
recommended and perceived advantages. Figure 38 integrates all three focus areas of the project: quality,
effectiveness, and efficiency.
Table 10. Summary of recommended actions, timeframe and direct benefits
WHEN ACTION IMPACT
- Eliminate the 20% assay repetition of potent compounds,Incorporate chemist's knowledge which equals almost 30% of CP's NVA time and an entire
about cmpd potency run for CM
Now Integrate equipment with available - Remove about 30 mins in CM's time (29% of NVA for CM)
information and 15 mins of CP's time (11% of NVA time for CP)
Change booking system procedures - Change process to full push flow
so that CP book time slots and CM - Reduce NVA time for CP by 10 mins
prepares based on that schedule
1.Decrease almost 40% in NVA time of CM (from 104 to 64
BENEFITS OF IMMEDIATE ACTIONS mins)
2. Decrease 41% in NVA time of CP (from 134 to 79 mins)
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(cont.) Table 10. Summary of recommended actions, timeframe and direct benefits
WHEN ACTION IMPACT
- Start tracking defined criteria to find special cause variation
Incorporate assay plate and cmpd and optimize internal processes
data validation criteria - Understand the assay performance and knowledge sharing
among associates
Next - Facilitate outlier and trend observations, eliminating assay
3-6 repetition
months Develop graphic controls - Relate any process change to a data point creating a learning
environment about impact of changes - knowledge sharing
among similar assays
Define procedures to asses outliers - Decrease assay repetition solicited by chemists (5% of
and find special cause variation realized assays)
1. Eliminate 5% of unnecessary cmpd testing = 11 mins for
BENEFITS OF MIDTERM ACTIONS CM and more than 13 mins for CP (complete cycles)
2. Change from reactive to proactive when aging of RC
Incorporate standard - Standardize definition of RC control limit
procedures in assay - Eliminate differences among associates so that best practices can be shared
development and assay profiling time is more stable
- Allow CP to select cmpds from TRT and book a robot. Results in freeing a
computer and eliminating 15 mins of CP's NVA time (11I%)
- Provide available times for robots and calculate needed times depending
Developon specific cmpds-assays, optimizing equipment usageDevlopashdln - Link robot's information to update availability (not used or down)
tool- Alarm new changes in robotic systems
Next - Provide information to CM eliminating 5 different Excel files, need for
year developing, and supporting macros internally. Eliminate 25 mins of CM
(24% of NVA time)
- Make final procedures available to all associates
Inertoansa R pcfccpsasyotmzn qimn sg
development tool with equire complete information such as dilution, enzymes in a panel, RC
the process used, and control limits, providing a complete report dataset for repetition
- Update of assay versions is constant and associates are aware of changes
Integrate data - Deliver email to chemists with a link to the database in the form needed
generation with data - Eliminate 10 to 20 mins of CP's NVA time (7-14%) and having the same
submission information in several places which currently leads to confusion about
updated results
1. Inform of timeframes for data submission
2. Close gap between mean and median values in about 2 days
3. Decrease turnaround times greater than 60 days in more than 50%
BENEFITS OF FUTURE 4. Decrease 39% in NVA time of CM(from 64 to 39 mins from previous
ACTIONS improvement)
5. Decrease almost 32% in NVA time of CP(from 79 to 54 mins from
previous improvement)
6. Decrease 30% in CP and CM total duration per assay plate produced
An important observation from the analysis in prior chapters is that process variability comes from the
current scheduling system and changing the planning procedures will allow to increase profiling time
predictability, even if assays have also variability in demand. The current process relies on steady-state
assumptions and flexible schedules to work around the variability in the number of compounds requested
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for profiling. This adaptability has created observed outliers and affected process reliability. It is proposed
to consider a rough estimation of 12 hours as the total process time (TPT) for the Biology lab, which ,
assuming that the production rate is about 14 compounds per day (a plate) per person, leads to an
optimization point 14 compounds. This means that, the best results are obtained when profiling processes
start whenever there are 14 compounds solicited for a particular panel. The 14 compound number is
known as process queue and will permit the lab to operate in a smoother activity phase.
Define Quality - KPI Chemists report on E[IC50] (range)
Changes in Helios: Centralized (web) communication among
SGraphical RC controlCM&CP&CH/machines:Sraic RCco l-More standard processes, best practices
- Estimated impact of RC aging sharing
- Ea - Share estimated data delivery date
U - Control on minor changes in RDS report forrepeatability among associatesUfiiec
- Emphasize process analysis and optimization 4 investment decisionL Centralized (web) communication among CM&CP&CH/machines:
- Scheduling based on capacity
- Information only at AD, only one place for info update and
modification
e Process standardization
Figure 38. Relation between recommendations the three areas of the project
Lastly, it has to be recognized that EPP/Biology lab has a great advantage of possessing all the knowledge
in house. Also, is characterized by associates with defined responsibilities and with the expertise, not only
for a great assay profiling but also for equipment support and software tool development. All this together
with some process monitoring and control, can lead to sustainable and impactful benefits for the overall
R&D length.
6.3. Internal challenges
Even when proposed changes are well defined and results are compelling, application can face with
people's personal perceptions and resistance towards change. The aim of the recommendations presented
is to provide a framework for improvement utilizing current momentum, but the limitation is that current
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- IC50 of cmpo/rjC/Sa
- Limit to post data given KPIs
- Report of minor profiling changes
momentum is also perceived for some as chaotic and unorganized. Thus, suggestions in this project can
be observed as more changes that will confuse further current procedures.
As concluded by many researchers, one of the most important drivers for productivity increase in science-
driven companies is motivation46 .When individual contribution is high and team cohesion is strong,
process upgrades are, not only more helpful, but sustainable. In this way, process changes are perceived
as a tool for better realizing day-to-day operations and their implementation becomes natural.
Another constraint for improvement is the individual owning of assays. Given that each assay is
performed by a particular associate, knowledge sharing can be perceived as lack of freedom or trust. For
the changes to be successful, an environment where everyone can measure the benefits from integration is
vital, so metrics have to be aligned to show the advantages of boosting team focus.
The last limitation can be observed when standardizing procedures. This standardization often times is
perceived as lack of trust, and may be seen as a limitation for innovation. When people are focused on
uniqueness of work, having common frameworks can decrease people's motivation and joy for new
projects. In order to overcome this mentality, a balanced measurement system, as the one recommended
in this project, is key for engaging associates while maintaining the innovation in the teams.
6.4. Future studies
This project is an initiation towards analyzing lab activities from a process perspective. As a result, many
areas were identified as potential topics for future projects:
1. Evaluation of the historic trends ofselectedKPIs: Recommended KPIs are a first approximation to
process monitoring and control, based on the current data available. In the future, it will be necessary to
revisit the impact and applicability of the recommended KPIs to ensure that these are still the best ones to
define the lab's performance.
2. Study of the shift of incentives and/or priorities: Even when changing current lab KPIs, each drug
discovery project relies on a group of people with different backgrounds, decision making procedures and
responsibilities. For a real decrease in the total duration of drug discovery, indicators for every
stakeholder should be aligned to reflect platform performance. Some of indicators that can help aligning
incentives are: number of sPOC/time, number of NMEs in new areas (to boost innovation) and speed of
decision making processes (measured even for stopped projects in order to know how useful the data is in
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making decisions and stopping projects on-time). Studies to evaluate the impact of having more aligned
KPIs can give more insight about the platform dynamics and make evident future areas for improvement.
3. Simulation of benefits: When noise of the process is reduced and measured outcomes are in control,
additional benefits can be obtained from process simulation. This tool will allow observation of critical
steps in the flow of activities and help differentiate key areas for improvement. Lastly, this application
can show the impact that any variation in the methods can have on the rest of the drug discovery loop.
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8. APPENDIX
Appendix A: Compound Manager Detailed Process Map
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Appendix B: Comp-ound Profiler Detailed Process Map
PRCS MA-PII*CMON PRFIE (1)
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PROCESS MAP-EPP-BIOICOMPOUND PROFILER (2)
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re empds too pote 
. CND]
and curves can't be YDL IN Back to stepa.
analyzed? DILUTION
14.1. Select all curve data and click on "set to publish"
14.2. Un select reference cmpds and any other data that won't be published
14.3. Store final results in databases
NO 14.4. Export the file to excel
14.5. Open Pharon . copy and paste exported data to excel and save file to post data in Avalon
M DATA 14.8. Save Excel file in CP personal folder14.7. Copy raw data in excel to generate another report for chemists ~~"""K
SUBi JSSION 14.8. Send email around to all team with last excel report
oes the assa Is chemist
needs to be YES--. generating anothe YES-+ Backto step1.
repeatedequest or omprepeated? batchbatch?
NO NO
Backto step1a
status of cmpds changes to
is-progress' and a work listfor
data analysis
Status of cmpds changes to
in-progress- and a work list for
dataanalysis
Ptate groupto analyze all
plates at a tIme
nalysis of resulted curves for
cmpds tested
Cmpd data avalable for
chemists
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Appendix C. Codes used in Process Mapping
Dedision points
Standardledtablished operation
Preparation
SW Manual operation not critical to the process
Manual operation that can impad the process outcome
Sum)iundion of steps
Manual operation that requires move from work station
E xernal ink
Manual lnput of infoldata
Waiting time
A document is generated or used
Starting or ending points or denotes inputs or outputs in adivities when accompanied by a dotted arrow
Sort
Process that hasto occur in order to cntinue adivities
Feedback to a previous adivity
Shows inputs or outputsthat are currently needed for a particular adivity
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Appendix D. Fishbone diagram for Turnaround time variation (mean and range)
PEOPLE EPP projects will be done firstthan rare requests from other DAs
Projects
have hig
Each La
prefere
P
s
with less priority
her profiling times
b Head may has d
nces and that chan
reference for
ome projects
CP do things depending
on Lab Head
\Need for inovat
Everybod
own proc
Assay development activities may
have priority depending on Lab Head
\ No sp
Z for pr
\ CP sc
depen
Fillin
CP tc
Errors in D
take time t
n
Direct requests from
make CP and CM loc
:EQUIPMENT
Booking is done in half days, not a
calculation of the real duration of the assays
ifferent
ges CP sciedule Sometimes people don't usethem and never update data
Robots can be booked for days
ion,
No communication channel
y has their when robot Is down
edure Too "iany constantZZ changes in software
ecific Schedule - Equipment is down
ofiling
hedule assays
ding on their workload WHY TRUNAROUND TIMES ARE
UNSTABLE AND UNPREDICTABLE?
Every CP flls in differel way
No better way \
to communicate
g out requests from
CM take time
Copy and paste or double
entry needs leads to errors
Checki in all excel files
to find cause of errors
RC requests
o solve
it of the established process
eed -tweaks- for system
chemists
se time
METHODS ENVIRONMENT
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Appendix E. Statistical Analysis for EPP/Biology turnaround times
Moods Median Test for Type of screening:
Mood Median Test: Time in EPP/Biology lab versus Type of screening
Hood median test for Y2-TIHE IN EPP/BIO
Chi-Square = 4007.46
X2-Type of
screening
Asi
As2
As4
Cy16
Cy4
Cy7
Cy8
Cy9
EP1
EPlO
EPil
EP12
EP13
EP14
EPis
EP16
EP17
EP18
EP19
EP20
EP21
EP22
EP23
EP24
EP25
EP26
EP27
EP3
EP4
EP5
EP6
EP7
EP8
EP9
Hel
HelO
Hell
He2
He6
He7
He9
Prl
SE1
Se13
Se14
Se16
Se17
Sel8
Se4
Se5
N<=
143
1
9
9
38
155
0
164
0
33
17
6
5
0
119
10
11
3
13
17
49
9
36
149
76
59
10
2
6
8
23
34
88
18
0
72
77
59
90
446
834
299
5
1943
6363
2
37
622
0
324
N>
196
2
6
102
49
147
165
10
2
210
15
0
0
1
25
3
1
0
48
0
40
15
39
80
55
54
9
21
4
13
18
41
83
5
1
0
8
20
0
117
185
841
2
181
4973
1
2
142
33
1312
DF = 47 P = 0.000
Hedian
5.0
10.0
1.0
8.0
6.0
4.0
8.0
1.0
6.5
5.0
4.0
2.5
2.0
7.0
2.0
4.0
2.5
4.0
6.0
3.0
4.0
5.0
5.0
4.0
4.0
4.0
4.0
6.0
3.0
6.0
4.0
5.0
4.0
1.0
38.0
1.0
4.0
2.0
2.0
3.0
2.0
7.0
4.0
2.0
4.0
2.0
2.0
2.0
20.0
10.0
03-01
9.0
23.0
4.0
1.0
8.0
8.0
1.0
3.0
3.0
4.0
2.0
2.3
1.0
Not Used
2.0
2.0
1.0
1.0
4.0
0.5
2.0
1.8
2.0
3.0
4.0
10.0
4.0
1.0
5.3
3.0
2.0
2.0
2.0
3.0
Not Used
0.0
1.0
4.0
0.0
3.0
3.0
7.0
2.0
1.0
5.0
86.0
1.0
2.0
22.0
12.0
Individual 95.0k CIs
+--------+---------+---------+---
*-)
*t
(ft
(*t
*
(ft
(*t
*t)
*t
ft
ft)
(-*t
*
(*t
*t
*
(*t
(*t
(*t)
*---------------------)
(*t
*t)
0 25 50 75
Overall median = 4.0
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Moods Median Test for Protocol type:
Mood Median Test: Time in EPP/Biology versus Protocol Code
Mood median test for Y2-TIME IN EPP/BIO
Chi-Square = 878.82 DF = I P = 0.000
03-01
2.00
6.00
Individual 95.0% CIs
-----------------------------------
*
23---------.------------------
2.40 3.00 3.60
Overall median = 4.00
A 95.0% CI for median(P) - median($): (-2.00,-2.00)
Moods Median Test for Profile type:
Mood Median Test: Y2-TIME IN EPPtBIO versus X3-PROFILE CODE
Mood median test for Y2-TIME IN EPP/BIO
Chi-Square = 2897.53 DF = 30 P = 0.000
03-01
0.0
9.0
4.0
1.0
2.0
3.0
2.0
11.0
5.0
4.0
2.0
3.0
3.0
1.8
2.0
3.0
6.8
4.0
3.0
3.0
7.0
1.0
7.0
13.0
4.0
5.0
3.0
7.0
6.0
7.0
2.0
Individual 95.0% CIs
------- +---------+---------+---------
*---)-
(--------------------)
*------------------
S+-------*-----)
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X4-PROTOCOL
CODE
P
S
N< =
2143
10350
N>
384
8893
Median
2.00
4.00
X3-PROFILE
CODE
EPI
EPIO
EPil
EP12
EP13
EP14
EP15
EP16
EP17
EP18
EP19
EP2
EP20
EP21
EP22
EP23
EP24
EP25
EP26
EP27
EP28
EP4
EPS
EP6
EP7
EP8
EP9
Pr5
Pr6
Pr7
SE1
N< =
22
55
33
5
137
830
10
82
741
13
188
0
66
9
866
185
135
10
54
402
719
2
353
271
4614
2379
8
67
93
139
5
N>
0
73
210
0
31
180
3
90
575
48
162
2
40
15
164
119
109
9
38
24
690
21
462
1265
2341
1750
13
224
231
386
2
Median
1.0
5.0
5.0
2.0
2.0
2.0
4.0
7.0
4.0
6.0
4.0
6.5
4.0
5.0
2.0
4.0
4.0
4.0
3.0
2.0
4.0
6.0
6.0
12.0
3.0
4.0
6.0
7.0
6.5
7.0
4.0
Moods Median Test for type of request (internal vs. external):
Mood Median Test: Y2-TIME IN EPP/BIO versus X1 -REO GROUP
Mood median test for Y2-TIME IN EPP/BIC
Chi-Square = 592.11 DF = 2 P = 0.000
Xl-REQ
GROUP
EPP/BIO
EPP/HCH
OTHER
N<=
4124
5360
3009
N>
1703
4679
2895
Median
2.00
4.00
4.00
03-01
3.00
5.00
6.00
Individual 95.0i CIs
2.0 3.0 4.0
Overall median = 4.00
Moods Median Test for Phase of Project:
Mood Median Test: Y2-TIME IN EPP/BIO versus X7-PHASE
Mood median test for Y2-TIHE IN EPP/BIO
Chi-Square = 801.11 DF = 9 P = 0.000
X7-PHASE
DI
D2a
D2b
D2b->D3
D3
(LEAD Candidate)
D3->CSP (CSP Candidate)
D4
DevSupport
ReferenceCpd
X7-PHASE
DO
Dl
D2a
D2b
D2b->D3 (LEAD Candidate)
D3
D3->CSP (CSP Candidate)
D4
Dev5upport
ReferenceCpd
Overall median = 4.00
K<=
922
1001
2916
5500
297
1501
334
11
3
8
N>
323
310
1747
4128
388
2052
274
25
9
21
Median
2.00
3.00
3.00
4.00
5.00
5.00
4.00
9.00
6.50
6.00
03-01
4.00
2.00
5.00
5.00
6.00
8.00
5.00
11.00
2.75
4.50
Individual 95.0k CIs
3.0 6.0
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5.0
9.0 12.0
*---------)
Moods Median Test for location (country):
Mood Median Test: Y2-TIME IN EPP/BIO versus COUNTRY
Hood median test for
Chi-Square = 226.75
COUNTRY
AT
CH
CN
GB
SG
N<=
0
11256
2
38
13
N>
30
8435
2
141
53
Y2-TIME IN EPP/BIO
DF = 5 P = 0.000
Hedian
12.00
4.00
5.50
7.00
7.00
03-01
7.00
5.00
6.00
3.00
2.25
Individual 95.0% CIs
--------------------------
us 1184 616 3.00 5.00 *
----------------------------------------
5.0 7.5 10.0
Overall median = 4.00
Mood Median Test: Y3-TOTAL TIME versus COUNTRY
Hood median test for Y3-TOTAL TIME
Chi-Square = 1031.44 DF = 5 P = 0.000
Individual 95.0% CIs
COUNTRY
AT
CH
CN
GB
SG
us
N<= N> Hedian
0 30 16.0
10699 8992 6.0
0 4 9.0
16 163 11.0
9 57 9.0
339 1461 9.0
03-01
7.0
6.0
6.3
5.0
4.0
5.0 (-*
6.0 9.0 12.0
Overall median = 6.0
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Appendix F. Minitab output for Process Capability study
F EPP/Biology Lab
Xba ehart C
1 LSL U
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Appendix G. Fishbone diagram for Quality of data
JMATERIALS
batch is known to be a
\ RC i
No automatic system to observe trends
Manual tracking is required
Some assays need a quick test
and data can't be thoroughly checked
rgent requests I "-- -
Assay is urgent, no ume to
test RC as needed before
Assay is new and RC profiing
behavior is not well defined
Data not available
If AC50 is out of range, batch of
RC is changed for next assay but
the current stays in the database
RC batch is changed
after observed data
METHODS
PlEOLE EQUIPMENT
When AC50 of RC is not clear
High UCULCL permits to
s aging work with no flags Robot dispensed
incorrect amounts
Projects in late phases require
more accuracy than cmpds in
early project phases
Lab technicians use different
tools to know if assay Is valid
No standard criteria, depends by assay conditions
on chemist and team
Projects/assays differ
Raadusare ffected
in acceptance criteria
i
No RIC available for
the conditions needed
ENVIRONMENT
-WHY RC DATA QUALITY CAN FAIL?
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Appendix H. Mood's Median Test for AC50 of selected
With respect to the experiment date
Results for: C1 In assay 62-1 Results for: C2 in assay 88-1
Mood Median Test: Qualified AC50 versus Experiment date Mood Median Test: Qualified AC50 versus Experiment date
Hood median test for Qualified ACSO
Chi-Square = 20.38 DF = 7 P = 0.005
Hood median test for Qualified AC50
Chi-Square = 39.14 DF = 17 P = 0.002
Experiment date
3-Mar-2009
10-Mar-2009
11-Mar-2009
16-Mar-2009
18-Har-2009
25-Mar-2009
1-Apr-2009
8-Apr-2009
Experiment date
3-Mar-2009
10-Mar-2009
ll-Mar-2009
16-Mar-2009
18-Har-2009
25-Mar -2009
1-Apr-2009
8-Apr-2009
Median
0.0004
0.0007
0.0009
0.0011
0.0006
0.0008
0.0008
0.0010
03-Ql
0.0005
0.0002
0.0000
0.0005
0.0003
0.0006
0.0006
0.0003
Individual 95.0% CIs
(-------
(- ) 0
0.00000 0.00050 0.00100 0.00150
Experiment date
4-Dec-2008
17-Dec-2008
18-Dec-2008
16-Jan-2009
23-Jan-2009
3-Feb-2009
10-Feb-2009
16-Feb-2009
24-Feb-2009
27-Feb-2009
4-Mar-2009
17-Mar-2009
24-Har-2009
1-Apr-2009
6-Apr-2009
17-Apr-2009
21-Apr-2009
22-Apr-2009
24-Apr-2009
30-Apr-2009
Individual 95.0$ CIs
(---------------*----------------)--
(-----*--------- *------------
-*-----
(*-- -- - -- )- - - - -- - - - - -
* ) (*)
(*)
(---*-)
3.0 6.0 9.0
With respect to the operator
Results for: C1 in assay 62-1
Mood Median Test: Qualified AC50 versus Operator
Hood median test for Qualified ACSO
Chi-Square = 6.49 DF = I P = 0.011
Individual 95.04 CIs
Operator N<= N> Median 03-01 ------ +---------+------------------+
A 40 34 0.0007 0.0004 (-*--)
B 6 0.0010 0.0003 (--------*---------------
0.00080 0.00100 0.00120 0.00140
Overall median = 0.0008
Results for: C5 in assay 70-1
Mood Median Test Qualified AC50 versus Operator
Hood median test for Qualified AC50
Chi-Square = 4.21 DF = I P = 0.040
Operator N<= N> Median
C 40 36 1.53
D 4 3.42
Overall median = 1.55
Individual 95.0% CIs
03-01 +-------+-------- +--------+-----
1.59 (-*)
2.21 --------------
3-------- .-8-+
1.2 2.4 3.6 4.8
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With respect to substrate batch
Results for: C2 in assay 88-1
Mood Median Test: Qualified AC50 versus Substrate Batch
Mood median test for Qualified AC50
Chi-Square = 0.75
Substrate Batch
BS-1
BS-2
DF = 1 P = 0.387
N<= N>
6 9
32 29
Median 03-1
4.13 3.57
3.06 1.14
Individual 95.0% CIs
Substrate Batch --------------------+ -------
BS-1 (--------------*----------
BS-2 |(-*-)
------------------------------
3.0 4.0 5.0
Overall median = 3.10
Results for: C4 in assay 90-1
Mood Median Test Qualified AC50 versus Substrate Batch
hood median test for Qualified ACSO
Chi-Square = 21.27 DF = I P = 0.000
N<= N> Median 03-01
21 2 0.061 0.048
20 38 0.248 0.121
Individual 95.0% CIs
------------- +---------+-----------
0.07 .140 0.10 28---0---)
0.070 0.140 0.210 0.280
Overall median = 0.209
With respect to timestamp
Results for: C4 in assay 90-1
Mood Median Test: Qualified AC50 versus Readout timestamp
Mood median test for Qualified AC50
Chi-Square = 52.33 DF = 18 P = 0.000
03-01
0.043
0.052
0.507
0.082
0.030
0.009
0.028
0.062
0.075
0.018
0.039
0.038
0.016
0.219
0.126
0.010
0.109
0.040
0.061
Individual 95.0% CIs
(-------*--------------------
(*---)
(*-)
(-)
(-------------------------------
0.00 0.20 0.40 0.60
Overall median = 0.209
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Substrate Batch
BS-3
BS-4
Readout
timestamp
04:28.0
04:30.0
10:18.0
12:25.0
17:05.0
20:38.0
24:31.0
27:36.0
28:08.0
32:12.0
42:23.0
44:42.0
46:27.0
46:45.0
48:06.0
48:10.0
52:20.0
57:51.0
58:26.0
N<=
0
0
2
3
0
2
4
0
2
4
3
1
4
7
0
4
1
0
4
Median
0.247
0.306
0.175
0.183
0.334
0.023
0.013
0.274
0.235
0.086
0.025
0.225
0.060
0.167
0.451
0.066
0.231
0.251
0.152
Mood Median Test: Qualified AC50 versus Readout timestamp
Hood median test for Qualified AC50
Chi-Square = 39.64
Readout
timestamp
04:04.0
07:30.0
07:36.0
07:44.0
11:12.0
11:58.0
17:49.0
20:56.0
22:09.0
25:47.0
34:39.0
36:22.0
38:22.0
38:40.0
39:22.0
41:02.0
42:45.0
43:07.0
48:04.0
50:55.0
51:12.0
59:35.0
N<=
0
4
1
0
2
3
0
4
3
2
2
3
I
1
1
2
3
0
4
0
DF = 19 P = 0.004
Median
3.7
2.2
2.3
4.2
2.9
2.8
4.4
2.8
2.7
2.5
3.0
3.4
1.9
6.1
4.0
3.0
2.6
3.7
3.3
2.4
5.4
3.0
03-01
0.5
0.3
Not Used
1.1
2.1
0.9
1.1
0.5
0.9
0.4
0.5
0.7
Not Used
9.8
1.8
6.9
1.7
1.2
0.4
0.5
0.9
0.5
Individual 95.0% CIs
------ --------------------------- - -. -
---------- - ------+-------
(-*)
*)
(-*-)
()
(*)
(*)
3.9---.---+
3.0 6.0 9.0
Overall median = 3.1
With respect to experiment time
Results for: C1 in assay 62-1
Mood Median Test: Qualified AC50 versus Experiment time (RED TO HOUR)
Hood median test for Qualified ACS0
Chi-Square = 8.11 DF = 4 P = 0.088
Median
0.0006
0.0008
0.0009
0.0005
0.0007
03-01
0.0001
0.0004
0.0002
0.0003
0.0003
Individual 95.0% CIs
-------------------+- +-----------------
------------- )
(------------- )
0.00060 0.00080 0.00100
Results for: C2 in assay 88-1
Mood Median Test: Qualified AC50 versus Experiment time (RED TO HOUR)
Hood median test for Qualified AC50
Chi-Square = 11.76 DF = 6 P = 0.068
Median
3.52
2.83
2.79
3.06
3.24
3.70
3.33
03-01
1.72
1.34
2.13
1.81
3.02
1.31
0.88
Individual 95.0% CIs
-------+---------+---------+---------
(+----------------
--- ) ---
(-------------------
(---------------------------
--------------------------------
.0----------
3.0 4.0 5.0
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Experiment
time (RED
TO HOUR)
11
12
13
16
17
Experiment
time (RED
TO HOUR)
11
12
13
14
15
16
17
Results for: C4 in assay 90-1
Mood Median Test Qualified AC50 versus Experiment time (RED TO HOUR)
Hood median test for Qualified ACSO
Chi-Square = 18.00 DF = 7 P = 0.012
Experiment
time (RED Individual 95.0! CIs
TO HOUR) <= N> Median 03-01 ------ +----------------------------+
11 2 0 0.123 0.022
12 9 5 0.178 0.125 ------
13 13 13 0.214 0.209 (---- -- -)
14 13 4 0.067 0.125 (-*-)
15 1 1 0.251 0.103
16 2 8 0.281 0.088
17 1 7 0.315 0.183 (-------*-----------
18 0 2 0.334 0.015
--------+ --- ----------- +
0.12 0.24 0.36 0.48
Results for: C5 in assay 70-1
Mood Median Test: Qualified AC50 versus Experiment time (RED TO HOUR)
Hood median test for Qualified AC50
Chi-Square 18.75 DF - 6 P = 0.005
Experiment
time (RED Individual 95.0; CIs
TO HOUR) N<= N> Median 03-01 ---- +---------+---------+---------+
11 1 7 2.22 0.66 (------
12 0 4 2.26 0.85 (-------
13 6 4 1.53 0.89 (---------*-)
14 17 9 1.27 1.31 (---------*---)
16 8 10 1.83 1.66 (-------*-------
17 7 1 0.50 0.33 V----)
21 1 5 2.53 1.23 (--------------------
2-----4--------- 
0.80 1.60 2.40 3.20
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With respect to assay plate name
Results for: C3 in assay 19-1
Mood Median Test: Qualified AC50 versus Assay plate name
Mood median test for Qualified AC50
Chi-Square 68.00 DF = 35 P = 0.001
Assay Individua
plate name N<= N> Median 03-01 +-------
PP00000049 2 0 0.058 0.006
PP00000050 0 2 0.105 0.064
PP00000051 2 0 0.065 0.001
PP00000052 1 1 0.076 0.010
PP00000053 2 0 0.067 0.001
PP00000054 0 2 0.101 0.008
PP10000121 2 0 0.042 0.003 )
PP10000122 2 0 0.043 0.001 *
PP10000123 2 0 0.050 0.003
PP10000124 2 0 0.050 0.002
PP10000125 2 0 0.049 0.010 (-*)
PP10000126 2 0 0.049 0.009
PP10000127 2 0 0.049 0.012 (-s-)
PP10000128 2 0 0.046 0.009 (*
PP10000154 2 0 0.041 0.004 (*
PP10000155 2 0 0.039 0.009 (-)
PP10000230 4 0 0.057 0.023
PP10000231 2 0 0.059 0.014
PP10000232 0 2 0.084 0.001
PP10000233 0 4 0.083 0.008
PP10000276 0 2 0.108 0.010
PP10000277 0 2 0.108 0.003
PP10000278 0 2 0.107 0.013
PP10000279 0 2 0.102 0.008
PP10000359 1 1 0.073 0.001
PP10000360 0 2 0.095 0.009
PP10000438 1 1 0.068 0.013
PP10000563
PP10000564
PP10000565
PP10000566
PP10000664
PP10000665
0 2 0.126 0.043
0 2 0.129 0.046
0 2 0.100 0.019
0 2 0.104 0.014
0 2 0.120 0.031
1 1 0.087 0.035
1 95.0% CIs
(~)
(It)
(*)
(------V-----)
0.035 0.070 0.105 0.140
Overall median = 0.073
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Results for: C5 in assay 70-1
Mood Median Test: Qualified AC50 versus Assay plate name
Hood median test for Qualified AC50
Chi-Square = 40.00 DF = 34 P 0.221
Assay Individual 95.0% CIs
plate name N<= N> Hedian 03-01 - -+-----------------------
PP00000065 2 0 0.36 0.04 (*
PP00000066 2 0 0.34 0.03 *)
PP20000001 2 0 0.64 0.12 *)
PP20000002 2 0 0.28 0.11 (*
PP20000003 2 0 0.44 0.14 *)
PP20000004 1 1 1.08 1.18 *
PP20000009 2 0 0.30 0.13 (*)
PP20000010 2 0 0.29 0.13 ()
PP20000011 2 0 0.36 0.27 (-*)
PP20000012 2 0 0.49 0.00 *
PP20000013 1 1 1.20 1.16 *-
PP20000014 1 1 1.28 1.29 (---------
PP20000015 1 1 1.33 0.56
PP20000016 1 1 1.20 0.79
PP20000018 1 1 1.53 0.03
PP20000020 0 2 2.55 0.08
PP20000021 0 2 1.82 0.38
PP20000022 1 1 1.78 0.98
PP20000023 0 2 1.98 0.59
PP20000024 0 2 2.24 0.56
PP20000025 0 2 2.32 0.29 (*-)
PP20000027 1 1 1.71 1.13 ----- )
PP20000028 1 1 1.94 1.51 ------ *-------
PP20000030 0 2 2.87 0.89
PP20000031 0 2 2.52 0.96
PP20000032 1 1 1.96 1.37 ------
PP20000033 2 0 1.35 0.20
PP20000034 1 1 1.49 2.02 --------- *---------
PP20000035 1 1 1.04 1.01 (----*----)
PP20000042 0 4 2.09 0.70
PP20000043 2 2 1.55 0.63
PP20000044 2 2 1.42 1.16 - ---------
PP20000045 1 1 1.92 1.02
PP20000046 0 2 1.83 0.31 (*-)
PP20000047 I 1 1.70 0.97
-------------------------------
1.0 2.0 3.0
Overall median = 1.53
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